Kamada (KMDA) 20-F 6 Mar 18 2017 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2017shares
Document And Entity Information
Entity Registrant Name	KAMADA LTD
Entity Central Index Key	1,567,529
Document Type	20-F
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	40,254,740
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 12,681	$ 9,968
Short-term investments	30,338	18,664
Trade receivables, net	30,662	19,788
Other accounts receivables	2,132	3,063
Inventories	21,070	25,594
Current Assets	96,883	77,077
Property, plant and equipment, net	25,178	22,579
Other long term assets	49	40
Non-Current Assets	25,227	22,619
Assets	122,110	99,696
Current Liabilities
Current maturities of loans and capital leases	614	412
Trade payables	18,036	16,277
Other accounts payables	5,820	5,614
Deferred revenues	4,927	4,903
Current Liabilities	29,397	27,206
Non-Current Liabilities
Loans and capital leases	1,370	1,364
Employee benefit liabilities, net	1,144	722
Deferred revenues	707	3,661
Non-Current Liabilities	3,221	5,747
Shareholders' Equity
Ordinary shares	10,400	9,320
Additional paid in capital	177,874	162,671
Capital reserve due to translation to presentation currency	(3,490)	(3,490)
Capital reserve from hedges	46	(27)
Capital reserve from available for sale financial assets	(4)	19
Capital reserve from share-based payments	9,566	9,795
Capital reserve from employee benefits	(337)	(81)
Accumulated deficit	(104,563)	(111,464)
Shareholder's Equity	89,492	66,743
Shareholder's Equity and Liabilities	$ 122,110	$ 99,696

Consolidated Statements of Prof

Consolidated Statements of Profit or Loss and Other Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Profit or loss [abstract]
Revenues from proprietary products	$ 79,559	$ 55,958	$ 42,952
Revenues from distribution	23,266	21,536	26,954
Total revenues	102,825	77,494	69,906
Cost of revenues from proprietary products	51,335	37,723	30,901
Cost of revenues from distribution	19,402	18,411	23,640
Total cost of revenues	70,737	56,134	54,541
Gross profit	32,088	21,360	15,365
Research and development expenses	11,973	16,245	16,530
Selling and marketing expenses	4,398	3,243	3,652
General and administrative expenses	8,273	7,353	6,607
Operating income (loss)	7,444	(5,481)	(11,424)
Financial income	500	469	463
Income (expense) in respect of currency exchange differences and derivatives instruments, net	(612)	127	625
Financial expense	(162)	(126)	(934)
Gain (loss) before taxes on income	7,170	(5,011)	(11,270)
Taxes on income	269	1,722
Net income (loss)	6,901	(6,733)	(11,270)
Items that may be reclassified to profit or loss in subsequent periods:
Gain (loss) on available for sale financial assets	(23)	(54)	63
Gain (loss) on cash flow hedges	329	47	71
Net amounts transferred to the statement of profit or loss for cash flow hedges	(256)	(73)	44
Items that will not be reclassified to profit or loss in subsequent periods:
Actuarial gain (loss) from defined benefit plans	(256)	(22)	22
Total comprehensive income (loss)	$ 6,695	$ (6,835)	$ (11,070)
Income (loss) per share attributable to equity holders of the Company:
Basic income (loss) per share	$ 0.18	$ (0.18)	$ (0.31)
Diluted income (loss) per share	$ 0.18	$ (0.18)	$ (0.31)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Share capital [Member]		Additional paid in capital [Member]	Conversion option in convertible debentures [Member]	Capital reserve from Available for sale financial assets [Member]	Capital reserve due to translation to presentation currency [Member]	Capital reserve from hedges [Member]	Capital reserve from share-based payments [Member]	Capital reserve from employee benefits [Member]	Accumulated deficit [Member]	Total
Balance at Dec. 31, 2014	$ 9,208		$ 158,417	$ 1,147	$ 10	$ (3,490)	$ (116)	$ 8,783	$ (81)	$ (93,461)	$ 80,417
Net income (loss)										(11,270)	(11,270)
Other comprehensive income (loss)					63		115		22		200
Total comprehensive income (loss)					63		115		22	(11,270)	(11,070)
Exercise of options into shares	112		2,674					(1,533)			1,253
Expiration of conversion option on convertible debentures			1,147	(1,147)
Cost of share-based payment								1,907			1,907
Balance at Dec. 31, 2015	9,320		162,238		73	(3,490)	(1)	9,157	(59)	(104,731)	72,507
Net income (loss)										(6,733)	(6,733)
Other comprehensive income (loss)					(54)		(26)		(22)		(102)
Total comprehensive income (loss)					(54)		(26)		(22)	(6,733)	(6,835)
Exercise of options into shares		[1]	433					(433)				[1]
Cost of share-based payment								1,071			1,071
Balance at Dec. 31, 2016	9,320		162,671		19	(3,490)	(27)	9,795	(81)	(111,464)	66,743
Net income (loss)										6,901	6,901
Other comprehensive income (loss)					(23)		73		(256)		(206)
Total comprehensive income (loss)					(23)		73		(256)	6,901	6,695
Exercise and forfeiture of share-based payment into shares	3		712					(712)			3
Issuance of ordinary shares, net of issuance costs	1,077		14,491								15,568
Cost of share-based payment								483			483
Balance at Dec. 31, 2017	$ 10,400		$ 177,874		$ (4)	$ (3,490)	$ 46	$ 9,566	$ (337)	$ (104,563)	$ 89,492
[1]	Represent an amount lower than $1.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016		Dec. 31, 2015
Cash Flows from Operating Activities
Net income (loss)	$ 6,901	$ (6,733)		$ (11,270)
Adjustments to the profit or loss items:
Depreciation and impairment	3,523	3,501		3,227
Financial expenses (income), net	274	(470)		(154)
Cost of share-based payment	483	1,071		1,907
Income tax expense	269	1,722
Gain from sale of property and equipment	(52)	(18)
Change in employee benefit liabilities, net	166	(87)		87
Adjustments to the profit or loss items	4,663	5,719		5,067
Changes in asset and liability items:
Decrease (increase) in trade receivables, net	(9,967)	3,489		(5,604)
Decrease in other accounts receivables	328	211		118
Decrease (increase) in inventories	4,524	742		(913)
Decrease (increase) in deferred expenses	594	(433)		(565)
Increase (decrease) in trade payables	(838)	(2,650)		887
Increase in other accounts payables	71	1,520		94
Increase (decrease) in deferred revenues	(2,930)	1,035		(2,405)
Changes in asset and liability items	(8,218)	3,914		(8,388)
Cash received (paid) during the year for:
Interest paid	(21)	(60)		(484)
Interest received	399	842		1,143
Taxes paid	(116)	(1,785)		(47)
Cash received (paid) during the year	262	(1,003)		612
Net cash provided by (used in) operating activities	3,608	1,897		(13,979)
Cash Flows from Investing Activities
Proceeds from sale of (investment in) short term investments, net	(11,501)	4,236		13,971
Purchase of property and equipment and intangible assets	(4,167)	(2,641)		(2,718)
Proceeds from sale of property and equipment	60	42
Net cash provided by (used in) investing activities	(15,608)	1,637		11,253
Cash Flows from Financing Activities
Proceeds from exercise of warrants and options	3		[1]	1,254
Receipt of long-term loans	279	1,701		197
Repayment of long-term loans	(530)	(211)		(9)
Repayment of convertible debentures				(7,797)
Proceeds from issuance of ordinary shares, net	15,568
Net cash provided by (used in) financing activities	15,320	1,490		(6,355)
Exchange differences on balances of cash and cash equivalent	(607)	(103)		(418)
Increase (decrease) in cash and cash equivalents	2,713	4,921		(9,499)
Cash and cash equivalents at the beginning of the year	9,968	5,047		14,546
Cash and cash equivalents at the end of the year	12,681	9,968		5,047
Significant non-cash transactions
Purchase of property and equipment through capital lease	282	132
Purchase of property and equipment	$ 1,681	$ 1,968
[1]	Represent an amount of less than 1 thousands

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2017
Disclosure of general [Abstract]
GENERAL	Note 1: - General a. General description of the Company and its activity Kamada Ltd. ("the Company") is a plasma-derived protein therapeutics company with an existing marketed product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a high purity, liquid form, as well as other plasma-derived proteins. The Company's flagship product is "Glassia". In addition to Glassia, Kamada has a product line consisting of six other products which are marketed in more than fifteen countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. The Company's activity is divided into two operating segments: Proprietary Products Develop and manufacture plasma-derived therapeutics and market them in more than 15 countries. Distribution Distribute imported drugs in Israel, which are manufactured by third parties, most of which are produced from plasma or its derivative products. The Company's securities are listed for trading on the Tel Aviv stock exchange and on the NASDAQ. b. The Company has three wholly-owned subsidiaries – Kamada Inc and Bio-Kam Ltd which are not active and Kamada Biopharma Limited. In addition the Company owns 74% of Kamada Assets Ltd ("Kamada Assets"). c. Definitions In these Financial Statements – The Company - Kamada Ltd. The Group - The Company and its subsidiaries. Subsidiary - A company which the Company has a control over (as defined in IFRS 10) and whose financial statements are consolidated with the Company's Financial Statements. Related parties - As defined in IAS 24. USD/$ - U.S. dollar. NIS - New Israeli Shekel

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2017
Disclosure of significant accounting policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	Note 2: - Significant Accounting Policies a. Basis of presentation of financial statements 1. These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Board. 2. Measurement basis: The Company's consolidated Financial Statements are prepared on a cost basis, except for financial instruments (including derivatives) at fair value through profit or loss and other comprehensive income such as available for sales financial assets, employee benefit assets and employee benefit liabilities. The Company has elected to present profit or loss items using the "function of expense" method. b . The Company's operating cycle is one year. c. The consolidated financial statements comprise the financial statements of companies that are controlled by the Company (subsidiaries). Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. The consolidation of the financial statements commences on the date on which control is obtained and ends when such control ceases. The financial statements of the Company and of the subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group. Significant intercompany balances and transactions and gains or losses resulting from intercompany transactions are eliminated in full in the consolidated financial statements. d. Functional currency, presentation currency and foreign currency 1. Functional currency and presentation currency The consolidated financial statements are presented in U.S. dollars, which is the Company's functional and presentation currency. 2. Transactions, assets and liabilities in foreign currency Transactions denominated in foreign currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost in a foreign currency are translated at the exchange rate at the date of the transaction. e. Cash equivalents Cash equivalents are considered as highly liquid investments, including unrestricted short-term bank deposits with an original maturity of three months or less from the date of purchase. f. Short-term investments: Short-term bank deposits with a maturity of more than three months from the deposit date but less than one year, available for sale financial investments (debentures) and financial assets held for trading at fair value through profit or loss (debentures and stocks). g. Allowance for doubtful accounts The allowance for doubtful accounts is determined in respect of specific debts whose collection, in the opinion of the Company's management, is doubtful. Impaired debts are derecognized when they are assessed as uncollectible. As of December 31, 2017 there was no allowance for doubtful accounts and as of December 31, 2016, the balance of allowance for doubtful accounts was $399 thousands. h. Inventories Inventories are measured at the lower of cost and net realizable value. The cost of inventories comprises costs of purchase of raw and other materials and costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business. Cost of inventories is determined as follows: Raw materials - At cost using the first-in, first-out method. Work in process - Direct costs and indirect costs calculated at average costs for the quarter of manufacturing including materials, labor and other direct and indirect manufacturing costs on the basis of each batch. Finished products - Direct costs and indirect costs calculated at average costs for quarter of manufacturing including materials, labor and other direct and indirect manufacturing costs on the basis of each batch. Purchased products - At cost on a "first in – first out" basis. The Company periodically evaluates the condition and age of inventories and accounts for impairment of inventories with a lower market value or which are slow moving. Research and development costs Research expenditures are recognized in profit or loss when incurred. An intangible asset arising from a development project or from the development phase of an internal project is recognized if the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale; the Company's intention to complete the intangible asset and use or sell it; the Company's ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; the availability of adequate technical, financial and other resources to complete the intangible asset; and the Company's ability to measure reliably the expenditure attributable to the intangible asset during its development. Since the Company development projects are often subject to regulatory approval procedures and other uncertainties, the conditions for the capitalization of costs incurred before receipt of approvals are not normally satisfied and therefore, development expenditures are recognized in profit or loss when incurred i . Revenue recognition Revenues are recognized in profit or loss when the revenues can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the Company and the costs incurred or to be incurred in respect of the transaction can be measured reliably. In cases where the Company operates as a principal supplier and it exposed to the risks and rewards associated with the transaction, revenues are presented on a gross basis. Revenues are measured at the fair value of the consideration received less any trade discounts, volume rebates and returns. The specific criteria for revenue recognition for the following types of revenues are: - Revenues from the sale of goods are recognized when all the significant risks and rewards of ownership of the goods have passed to the buyer and the seller no longer retains continuing managerial involvement. The delivery date is usually the date on which ownership passes. - Agreements with multiple elements provide for varying consideration terms, such as upfront payments and milestone payments. Revenues from such agreements that do not contain a general right of return and that are composed of multiple elements such as distribution exclusivity, license and services are allocated to the different elements and are recognized in respect of each element separately. An element constitutes a separate accounting unit if and only if it has a separate value to the customer. Revenue from the different element is recognized when the criteria for revenue recognition have been met and only to the extent of the consideration that is not contingent upon completion or performance of future services in the contract. Revenue from milestone and upfront events stipulated in the agreements is recognized upon the occurrence of a substantive element specified in the agreement or as a measure of substantive progress towards completion. In events that the Company receives at no charge raw material, that is required for manufacturing one of the Company's products, the Company recorded the fair value of the raw material used and sold as revenue and charged the same fair value to cost of revenue. Deferred revenues Deferred revenues include unearned amounts received from customers not yet recognized as revenues. j. Taxes on income Taxes on income in profit or loss comprise current and deferred taxes. Current or deferred taxes are recognized in profit or loss, except to the extent that the tax arises from items which are recognized directly in other comprehensive income or in equity. 1. Current taxes: The current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the end of reporting period as well as adjustments required in connection with the tax liability in respect of previous years. 2. Deferred taxes: Deferred taxes are computed in respect of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes. Deferred taxes are measured at the tax rates that are expected to apply when the asset is realized or the liability is settled, based on tax laws that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets are reviewed at the end of each reporting period and reduced to the extent that it is not probable that they will be utilized. Temporary differences for which deferred tax assets had not been recognized are reviewed at the end of each reporting period and a respective deferred tax asset is recognized to the extent that their utilization is probable. Deferred taxes are offset in the statement of financial position if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority. k. Leases The Group as lessee: 1. Finance lease Finance leases transfer to the Company substantially all the risks and benefits incidental to ownership of the leased asset. At the commencement of the lease term, the leased assets are measured at the fair value of the leased asset or, if lower, at the present value of the minimum lease payments. The leased asset is depreciated over the shorter of the lease term and the expected life of the leased asset. 2. Operating lease Lease agreements are classified as an operating lease if they do not transfer substantially all the risks and benefits incidental to ownership of the leased asset. Lease payments are recognized as an expense in profit or loss on a straight-line basis over the lease term. l. Property, plant and equipment Property, plant and equipment are measured at cost, including directly attributable costs and financing costs, less accumulated depreciation, accumulated impairment losses and any related investment grants and excluding day-to-day servicing expenses. Cost includes spare parts and auxiliary equipment that can be used only in connection with the plant and equipment. The Company's assets include computer systems comprising hardware and software. Software forming an integral part of the hardware to the extent that the hardware cannot function without the programs installed on it is classified as property, plant and equipment. In contrast, software that adds functionality to the hardware is classified as an intangible asset. The cost of assets includes the cost of materials, direct labor costs, as well as any costs directly attributable to bringing the asset to the location and condition necessary for it to operate in the manner intended by management. Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Mainly Buildings 2.5-4 4 Machinery and equipment 10-20 15 Vehicles 15 15 Computers, software, equipment and office furniture 6-33 33 Leasehold improvements (* ) 10 (*) Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement. The useful life, depreciation method and residual value of an asset are reviewed at the year-end and any changes are accounted for prospectively as a change in accounting estimate. Depreciation of an asset ceases at the earlier of the date that the asset is classified as held for sale and the date that the asset is derecognized. m. Impairment of non-financial assets The Company evaluates the need to record an impairment of the carrying amount of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable. If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. An impairment loss of an asset, is reversed only if there have been changes in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognized. Reversal of an impairment loss, as above, shall not be increased above the lower of the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized for the asset in prior years and its recoverable amount. n. Financial instruments 1. Financial assets Financial assets within the scope of IAS 39 are initially recognized at fair value plus directly attributable transaction costs, except for financial assets measured at fair value through profit or loss. After initial recognition, the accounting treatment of financial assets is based on their classification as follows: a. Financial assets at fair value through profit or loss Financial assets held for trading and derivative instruments that do not qualify for hedge accounting. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in the near term. b. Receivables The Company has receivables that are financial assets with fixed or determinable payments that are not quoted in an active market. c. Available for sale ("AFS") financial investments AFS financial investments include debt securities. Debt securities in this category are those that are intended to be held for an indefinite period of time and that may be sold in response to needs for liquidity or in response to changes in the market conditions. The Company has classified all marketable securities as short-term, even though the stated maturity date may be one year or more beyond the current balance sheet date, because it may sell these securities prior to maturity to meet liquidity needs or as part of risk versus reward objectives. After initial measurement, AFS financial investments are subsequently measured at fair value with unrealized gains and losses recognized in other comprehensive income ("OCI") until the investment is derecognized For AFS financial investments, the Company assesses at each reporting date whether there is objective evidence that an investment is impaired. For debt instruments classified as AFS financial assets, objective evidence of impairment may arise as a result of one or more events that have a negative impact on the estimated future cash flows of the asset since the recognition of the asset. Where there is evidence of impairment, the cumulative loss - measured as the difference between the acquisition cost and the fair value - is reclassified from other comprehensive income and recognized as an impairment loss in profit or loss. In a subsequent period, the amount of the impairment loss is reversed if the increase in fair value can be related objectively to an event occurring after the impairment was recognized. The amount of the reversal, up to the amount of any previous impairment, is recorded in profit or loss. 2. Financial liabilities Financial liabilities within the scope of IAS 39 are initially measured at fair value. After initial recognition, the accounting treatment of financial liabilities is based on their classification as follows: a. Financial liabilities measured at amortized cost Loans, including capital leases, are measured based on their terms at amortized cost using the effective interest method taking into account directly attributable transaction costs. b. Financial liabilities measured at fair value Derivatives, including separated embedded derivatives, are classified as held for trading unless they are designated as effective hedging instruments. 3. Fair value Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: - Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities. - Level 2 - inputs other than quoted prices included within Level 1 that are observable either directly or indirectly. - Level 3 - inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data). 4. Offsetting financial instruments Financial assets and financial liabilities are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously. The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that will cause the right to expire. 5. De-recognition of financial instruments a. Financial assets A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire or the Company has transferred its contractual rights to receive cash flows from the financial asset or assumes an obligation to pay the cash flows in full without material delay to a third party and has transferred substantially all the risks and rewards of the asset, or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset. b. Financial liabilities A financial liability is derecognized when it is extinguished, that is when the obligation is discharged or cancelled or expires. A financial liability is extinguished when the debtor (the Company) discharges the liability by paying in cash, other financial assets, goods or services or is legally released from the liability. o. Derivative financial instruments designated as hedges The Company enters into contracts for derivative financial instruments such as forward currency contracts and cylinder strategy in respect of foreign currency to hedge risks associated with foreign exchange rates fluctuations. Such derivative financial instruments are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. At the inception of a hedge relationship, the Company formally designates and documents the hedge relationship to which the Company wishes to apply hedge accounting and the risk management objective and strategy for undertaking the hedge. The hedge effectiveness is assessed at the end of each reporting period. Cash flow hedges The effective portion of the gain or loss on the hedging instrument is recognized as other comprehensive income (loss), while any ineffective portion is recognized immediately in profit or loss. Amounts recognized as other comprehensive income (loss) are reclassified to profit or loss when the hedged transaction affects profit or loss, such as when the hedged income or expense is recognized or when a forecast payment occurs. If the forecast transaction or firm commitment is no longer expected to occur, amounts previously recognized in equity are reclassified to profit or loss. If the hedging instrument expires or is sold, terminated or exercised, or if its designation as a hedge is revoked, amounts previously recognized in equity remain in equity until the forecast transaction or firm commitment occurs. p . Accrued expenses A provision in accordance with IAS 37 is recognized when the Group has a present (legal or constructive) obligation as a result of a past event, it is expected to require the use of economic resources to clear the obligation and a reliable estimate can be made of it. r. Employee benefit liabilities The Company has several employee benefit plans: 1. Short-term employee benefits Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made. 2. Post-employment benefits The post-employment benefits plans are normally financed by contributions to insurance companies and classified as defined contribution plans or as defined benefit plans. The Company has defined contribution plans pursuant to Section 14 to the Israeli Severance Pay Law under which the Company pays fixed contributions to certain employees under section 14 and will have no legal or constructive obligation to pay further contributions. Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed concurrently with performance of the employee's services. In addition the Company operates a defined benefit plan in respect of severance pay pursuant to the Israeli Severance Pay Law. According to the Law, employees are entitled to severance pay upon dismissal or retirement. The liability for termination of employment is measured using the projected unit credit method. The amounts are presented based on discounted expected future cash flows using a discount rate determined by reference to market yields at the reporting date on high quality corporate bonds that are linked to the Consumer Price Index with a term that is consistent with the estimated term of the severance pay obligation. In respect of its severance pay obligation to certain of its employees, the Company makes current deposits in pension funds and insurance companies ("the plan assets"). Plan assets comprise assets held by a long-term employee benefit fund or qualifying insurance policies. Plan assets are not available to the Company's own creditors and cannot be returned directly to the Company. The liability for employee benefits shown in the statement of financial position reflects the present value of the defined benefit obligation less the fair value of the plan assets. Re-measurements of the net liability are recognized in other comprehensive income in the period in which they occur. q. Share-based payment transactions The Company's employees and other service providers are entitled to remuneration in the form of equity-settled share-based payment transactions. Equity-settled transactions The cost of equity-settled transactions (options and restricted shares) with employees is measured at the fair value of the equity instruments granted at grant date. The fair value of options is determined using a standard option pricing model. The fair value of restricted shares is determined using the share price at the grant date. As for other service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments. In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, they are measured by reference to the fair value of the equity instruments granted. The cost of equity-settled transactions is recognized in profit or loss together with a corresponding increase in shareholder's equity during the period which the performance and/or service conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award ("the vesting period"). The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for awards that do not ultimately vest. If the Company modifies the conditions on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date. r. Income (loss) per Share Income (loss) per share is calculated by dividing the income (loss) attributable to Company shareholders by the weighted number of outstanding ordinary shares during the period. Ordinary shares underlying shares options or restricted Shares are only included in the calculation of diluted income (loss) per share when their impact dilutes the income (loss) per share. Furthermore, potential ordinary shares converted during the period are included under diluted income (loss) per share only until the conversion date, and from that date on are included under basic income (loss) per share. s. Reclassification of prior years' amounts Certain amounts in prior years' financial statements have been reclassified to conform to the current year's presentation. The reclassification had no effect on previously reported net loss or shareholders' equity.

SIGNIFICANT ACCOUNTING JUDGMENT

SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS	12 Months Ended
	Dec. 31, 2017
Disclosure of significant accounting judgments, estimates and assumptions used in the preparation of the financial statements [Abstract]
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS	Note 3: - Significant accounting judgments, estimates and assumptions used in the preparation of the financial statements Judgments Revenue The Company assesses the criteria for recognition of revenue related to up-front payments and multiple components as outlined by IAS 18, Revenue. Judgment is necessary to determine over which period the Company will satisfy its obligations related to up-front payments and when components can be recognized separately and the allocation of the related consideration to each component. For additional information, refer to Note 17a. Estimates and assumptions The key assumptions made in the financial statements concerning uncertainties at the end of the reporting period and the critical estimates computed by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. - Legal claims In estimating the likelihood of outcome of legal claims filed against the Company and its investees, the Company relies on the opinion of its legal counsel. These estimates are based on the legal counsel's best professional judgment, taking into account the stage of proceedings and historical legal precedents in respect of the different issues. Since the outcome of the claims will be determined in courts, the results could differ from these estimates. - Pensions and other post-employment benefits The liability in respect of post-employment defined benefit plans is determined using actuarial valuations. The actuarial valuation involves making assumptions about, among others, discount rates, expected rates of return on assets, future salary increases and mortality rates. Due to the long-term nature of these plans, such estimates are subject to significant uncertainty. - Determining the fair value of share-based payment transactions Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model including the expected life of the share option or appreciation right, volatility and dividend yield and making assumptions about them. - Provisions for clinical trial and related expenses Accrued expenses costs for clinical trial activities performed by third parties, are based on estimates on the progress of completion of the clinical trials or services, as of the end of each reporting period, pursuant to the contract with the third parties, and the agreed upon fee to be paid for such services. - Capitalization of materials for clinical trials and inventory designated for R&D activities The Company recognizes inventory produced for commercial sale, including costs incurred prior to regulatory approval but subsequent to the filing of a regulatory request when the Company has determined that the inventory has probable future economic benefit. Inventory is not recognized prior to completion of a phase III clinical trial. For products with an approved indication, raw materials and purchased drug product associated with development programs are included in inventory and charged to research and development expense when consumed. For products without an approved indication, drug product is charged to research and development expense.

DISCLOSURE OF NEW IFRS IN THE P

DISCLOSURE OF NEW IFRS IN THE PERIOD	12 Months Ended
	Dec. 31, 2017
Disclosure of new ifrs in the period [Abstract]
DISCLOSURE OF NEW IFRS IN THE PERIOD	Note 4: - Disclusure Of New Ifrs In The Period a. IFRS 15 – Revenues from contracts with customers The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the Company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and improve guidance for multiple-element arrangements. IFRS 15 is to be applied retrospectively for annual periods beginning on or after January 1, 2018. IFRS 15 allows an entity to choose to apply a modified retrospective approach. During 2017, the Company performed an assessment of IFRS 15 impact as described below. The Company is in the business of sale of plasma-derived therapeutics products and distribution in Israel of drugs manufacture by other companies. The products are sold on their own in separate identified contracts with customers. In addition, the Company received certain milestone and advances from Commercialization, Distribution and License Agreements with strategic partners. The Company performed the following preliminary assessment of IFRS 15: (1) Sale of goods Application of the IFRS 15 to contracts with customers in which the sale of product is generally expected to be the only performance obligation does not have any impact on the Company’s profit or loss following implementation of IFRS 15. The revenue recognition occurs at a point in time when control of the asset is transferred to the customer, generally on delivery of the goods. In implementation of IFRS 15, the Company is considering the following: (1) Variable consideration Some contracts with customers provide a right of return, trade discounts or volume rebates. Currently, the Company recognizes revenue from the sale of goods measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates. If revenue cannot be reliably measured, the Company defers revenue recognition until the uncertainty is resolved. Such provisions give rise to variable consideration under IFRS 15, which will be required to be estimated at contract inception. IFRS 15 requires that the variable consideration be estimated conservatively to prevent over-recognition of revenue. The Company continues to assess individual contracts to determine the estimated variable consideration and related constraint. There is no impact of IFRS 15on the financial statements. (2) Upfront and milestone payments Agreements with strategic partners that include upfront and milestone payments contain a performance obligation that is satisfied over time given that the customer simultaneously receives and consumes the benefits provided by the Company. Currently, the Company defers the upfront payments and recognizes revenue over time by reference to the stage of completion. Under IFRS 15, the Company would continue to recognize revenue for upfront payments over time rather than at a point of time. The Company identified the existence of a significant financing component resulting from an upfront payment. As of January 1, 2018 an amount of $ 757 thousands will be recognized as an increase of the deferred revenue against accumulated deficit and through 2018 will be recognize as revenue in the financial statements. Other than the financing component, there was no impact on the financial statement due to IFRS 15 implementation. (3) Presentation and disclosure requirements IFRS 15 provides presentation and disclosure requirements, which are more detailed than under current IFRS. The presentation requirements represent a significant change from current practice and may significantly expand the disclosures required in Company’s financial statements. Many of the disclosure requirements in IFRS 15 are completely new. In 2017 the Company updated the internal controls, policies and procedures necessary to collect and disclose the required information. b. IFRS 9 - Financial Instruments In July 2014, the IASB completed the final element of its comprehensive response to the financial crisis by issuing IFRS 9 Financial Instruments. The package of improvements introduced by IFRS 9 includes a logical model for classification and measurement, a single, forward-looking ‘expected loss’ impairment model and a substantially-reformed approach to hedge accounting. Certain securities that are currently measured at Fair Value through profit and lost will be measured at Fair Value through other comprehensive income (loss) due to implementation of IFRS 9. In addition, the Company will measure expected credit loss of the securities that will be measured at fair value through other comprehensive income (loss) . IFRS 9 is to be applied for annual periods beginning on January 1, 2018. The Company does not there to be any material impact from the adoption of IFRS 9 on the financial statements. c. IFRS 16 – Leases In January 2016, the IASB issued IFRS 16, Leases. IFRS 16, that replaces IAS imply small right The new Standard is effective for annual periods beginning on or after January 1, 2019. Earlier application is permitted provided that IFRS 15, "Revenue from Contracts with Customers", is applied concurrently. The Company is evaluating the possible impact of IFRS 16 but is presently unable to assess its effect, on the financial statements. d. IFRIC Interpretation 23 - Uncertainty over Income Tax Treatment The Interpretation clarifies application of recognition and measurement The interpretation is effective for annual reporting periods beginning on or after 1 January 2019. The Company is evaluating the possible impact of IFRIC Interpretation 23 but is presently unable to assess its effect, on the financial statements.

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS	12 Months Ended
	Dec. 31, 2017
Cash and cash equivalents [abstract]
CASH AND CASH EQUIVALENTS	Note 5: - Cash And Cash Equivalents December 31, 2017 2016 In thousands Cash and deposits for immediate withdrawal $ 8,539 $ 7,891 Cash equivalents in USD deposits (1) 4,001 2,001 Cash equivalents in NIS deposits (2) 141 76 $ 12,681 $ 9,968 (1) The deposits bear interest of 1.53% and 1.12% per year, as of December 31, 2017 and 2016, respectively. (2) The deposits bear interest of 0.01% per year, as of each December 31, 2017 and 2016.

SHORT-TERM INVESTMENTS

SHORT-TERM INVESTMENTS	12 Months Ended
	Dec. 31, 2017
Disclosure of short-term investments [Abstract]
SHORT-TERM INVESTMENTS	Note 6: - Short-Term Investments December 31, 2017 2016 In thousands Marketable securities (equity and debt) at fair value through profit or loss $ 1,663 $ 1,490 Bank deposits in USD (1) 20,078 8,010 Available for sale debt securities 8,597 9,164 $ 30,338 $ 18,664 (1) The deposits bear interest of 1.70%-2.3% and 1.69 %

TRADE RECEIVABLES, NET

TRADE RECEIVABLES, NET	12 Months Ended
	Dec. 31, 2017
Trade and other current receivables [abstract]
TRADE RECEIVABLES, NET	Note 7: - Trade Receivables, net December 31, 2017 2016 In thousands Open accounts: In NIS $ 8,263 $ 9,326 In USD 22,284 10,816 30,547 20,142 Checks receivable 115 45 30,662 20,187 Less allowance for doubtful accounts (1) - (399 ) Trade receivables, net $ 30,662 $ 19,788 (1) Allowance for doubtful accounts: December 31, 2016 $ (399 ) Bad debt recognition 399 December 31, 2017 $ - An analysis of past due but not impaired trade receivables with reference to reporting date: Past due trade receivables with aging of Neither past due nor impaired Up to 30 Days 30-60 Days 60-90 Days 90-120 Days Over 120 days Total In thousands December 31, 2017 $ 29,692 680 $ 21 $ 152 $ 2 $ - $ 30,547 December 31, 2016 $ 17,769 1,891 $ 24 $ 43 $ 6 $ 10 $ 19,743

OTHER ACCOUNTS RECEIVABLES

OTHER ACCOUNTS RECEIVABLES	12 Months Ended
	Dec. 31, 2017
Disclosure of other accounts receivables [Abstract]
OTHER ACCOUNTS RECEIVABLES	Note 8: - Other accounts Receivables December 31, 2017 2016 In thousands Materials for clinical trials and inventory designated for R&D activities $ 635 $ 1,229 Prepaid expenses 822 1,057 Government authorities 563 374 Accrued interest 66 82 Other 46 321 $ 2,132 $ 3,063

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2017
Classes of current inventories [abstract]
INVENTORIES	Note 9: – Inventories December 31, 2017 2016 In thousands Finished products $ 5,168 $ 6,542 Purchased products 2,695 5,607 Work in progress 6,159 6,227 Raw materials 7,048 7,218 $ 21,070 $ 25,594 (1) During the years 2017, 2016 and 2015, the Company recognized, at cost of revenues, as impairment for inventories carried at net realizable value totaled of $460 thousands, $544 thousands and $470 thousands, respectively.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about property, plant and equipment [abstract]
PROPERTY, PLANT AND EQUIPMENT	Note 10: – Property, Plant and equipment a. Composition and movement: 2017 Land and Buildings(1) Machinery and Equipment (1) (2) Vehicles Computers, Software, Equipment and Office Furniture Leasehold Improvements Total In thousands Cost Balance at January 1, 2017 $ 27,618 $ 26,485 $ 94 $ 5,520 $ 1,052 $ 60,769 Additions 781 3,151 - 1,002 1,196 6,130 Sale and write-off - (34 ) (28 ) - (975 ) (1,037 ) Balance as of December 31, 2017 28,399 29,602 66 6,522 1,273 65,862 Accumulated Depreciation Balance as of January 1, 2017 12,606 19,972 86 4,559 967 38,190 Depreciation and impairment 1,310 1,492 1 635 85 3,523 Sale and write-off - (34 ) (28 ) - (967 ) (1,029 ) Balance as of December 31, 2017 13,916 21,430 59 5,194 85 40,684 Depreciated cost as of December 31, 2017 $ 14,483 $ 8,172 $ 7 1,328 $ 1,188 $ 25,178 2016 Land and Buildings(1) Machinery and Equipment (1) (2) Vehicles Computers, Software, Equipment and Office Furniture Leasehold Improvements Total In thousands Cost Balance at January 1, 2016 $ 26,701 $ 24,111 $ 94 $ 5,156 $ 1,079 $ 57,141 Additions 963 3,220 - 507 62 4,752 Sale and write-off (46 ) (846 ) (143 ) (89 ) (1,124 ) Balance as of December 31, 2016 27,618 26,485 94 5,520 1,052 60,769 Accumulated Depreciation Balance as of January 1, 2016 11,237 19,310 83 4,136 1,012 35,778 Depreciation and impairment 1,402 1,355 3 564 44 3,368 Sale and write-off (33 ) (693 ) (141 ) (89 ) (956 ) Balance as of December 31, 2016 12,606 19,972 86 4,559 967 38,190 Depreciated cost as of December 31, 2016 $ 15,012 $ 6,513 $ 8 961 $ 85 $ 22,579 (1) Including labor costs charged in 2017 and 2016 to the cost of facilities, machinery and equipment in the amount of $431 thousands and $510 thousands, respectively. (2) Including financing costs of $44 thousands and $11 thousands capitalized in 2017 and 2016 respectively, to the cost of machinery and equipment. b. As for liens, refer to Note 18. c. Capitalized leasing rights of land from the Israel land administration. December 31, 2017 2016 In thousands Under finance lease $ 1,016 $ 1,029 The Group has capitalized leasing rights from the Israel Land Administration for an area of 16,880 m² in Beit Kama containing the Group's structures. The sum attributed to capitalized rights is presented under property, plant and equipment and is depreciated over the leasing period, which includes the option period. During 2010, the Company signed an agreement with the Israel Land Administration to consolidate its leasing rights and extend the lease period to 2058, including an extension option for additional 49 years

OTHER LONG TERM ASSETS

OTHER LONG TERM ASSETS	12 Months Ended
	Dec. 31, 2017
Miscellaneous non-current assets [abstract]
OTHER LONG TERM ASSETS	Note 11: - Other Long Term Assets December 31, 2017 2016 In thousands Long term pre-paid expenses $ 49 $ 40

TRADE PAYABLES

TRADE PAYABLES	12 Months Ended
	Dec. 31, 2017
Trade and other current payables [abstract]
TRADE PAYABLES	Note 12: - Trade Payables December 31, 2017 2016 In thousands Open debts mainly in USD $ 11,246 $ 11,187 Open debts in NIS 6,789 5,038 18,035 16,225 Notes payable 1 52 $ 18,036 $ 16,277

OTHER ACCOUNTS PAYABLES

OTHER ACCOUNTS PAYABLES	12 Months Ended
	Dec. 31, 2017
Disclosure of other accounts payable [Abstract]
OTHER ACCOUNTS PAYABLES	Note 13: – Other accounts Payables December 31, 2017 2016 In thousands Employees and payroll accruals $ 4,735 $ 4,135 Derivatives financial instruments 8 32 Accrued Expenses and Others 1,077 1,447 $ 5,820 $ 5,614

LOANS AND CAPITAL LEASES

LOANS AND CAPITAL LEASES	12 Months Ended
	Dec. 31, 2017
Disclosure of loans and capital leases [abstract]
LOANS AND CAPITAL LEASES	Note 14: - Loans and capital leases December 31, 2017 2016 In thousands Total loans and capital leases (1) 1,984 1,776 Less current maturities 614 412 Long term loans and capital leases $ 1,370 $ 1,364 (1) The capital lease balance was $274 thousands and $103 thousands, as of December 31, 2017 and 2016, respectively. Bank loans During 2017 and 2016, the Company received loans at an amount of NIS 1,000 thousands ($279 thousands) and NIS 6,585 thousands ($ 1,701 thousands). The loans are

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about financial instruments [abstract]
FINANCIAL INSTRUMENTS	Note 15: - Financial Instruments a. Classification of financial assets and liabilities The financial assets and financial liabilities in the balance sheet are classified by groups of financial instruments in pursuant to IAS 39: December 31, 2017 2016 In thousands Financial assets Financial assets at fair value through profit or loss: Marketable securities (equity and debt) $ 1,663 $ 1,490 Financial assets at fair value through other comprehensive income (loss)- Available for sale 8,597 9,164 Financial assets at cost: Cash 8,539 7,891 Short term bank deposits 24,220 10,087 $ 43,019 $ 28,632 Financial liabilities Financial liabilities at fair value: Derivatives instruments $ 8 $ 32 Financial liabilities measured at amortized cost: Bank loans and capital leases 1,984 1,776 $ 1,992 $ 1,808 b. Financial risk factors The Company's activities expose it to various financial risks, such as market risk (foreign currency risk, interest rate risk and price risk), credit risk and liquidity risk. The Company's investment policy focuses on activities that will preserve the Company's capital. The Company utilized derivatives to hedge certain exposures to risk. Risk management is the responsibility of the Company CEO and CFO, in accordance with the policy approved by the Board of Directors. The Board of Directors provides principles for the overall risk management. 1. Market risks a) Foreign exchange risk The Company operates in an international environment and is exposed to foreign exchange risk resulting from the exposure to different currencies, mainly the NIS. Foreign exchange risks arise from recognized assets and liabilities denominated in a foreign currency other than the functional currency, such as customers, suppliers and credit. As of December 31, 2017, the Company has a position in financial derivatives intended to hedge changes in the exchange rate of the USD vs. the NIS (see also f. below). b) Price risk As of December 31, 2017, the Company has financial instruments, shares and debentures, classified as financial assets measured at fair value through profit or loss and Available for sale financial investments for which the Company is exposed to risk of fluctuations in the security price that is determined by reference to the quoted market price. 2. Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, short-term bank deposits, marketable securities, trade receivables and foreign currency derivative contracts. a) Trade receivables: The Company regularly monitors the credit extended to its customers and their general financial condition, and, when necessary, requires collateral as security for these debts such as letters of creditor and down payments. In addition, the Company partially insures its overseas sales with foreign trade risk insurance. The Company keeps constant track of customer debt and the Financial Statements include an allowance for doubtful accounts that adequately reflects, in the Company's assessment, the loss embodied in the debts the collection of which is in doubt. The Company’s maximum exposure to credit risk for the components of the statement of financial position as of December 31, 2017 and 2016 is the carrying amount of trade receivables. b) Cash and cash equivalent and short term investments: The Company holds cash, cash equivalents, short term deposits and other financial instruments at a major financial institutions in Israel. In accordance with Company policy, evaluations of the relative strength of credit of the various financial institutions are made on an ongoing basis. Short-term investments include short-term deposits with low risk for a period less than one year. The Company’s marketable securities consist of investment-grade corporate bonds, U.S., European and Israeli governments bonds and equity investments. The Company’s investment policy, limits the amount the Company may invest in any one type of investment or issuer and the average maturities of the bond portfolio, thereby reducing credit risk concentrations. The Company has not experienced any significant losses on its short term investments. c) Foreign currency derivative contracts: The Company is exposed to foreign currency exchange movements, primarily in Israel. Consequently, it enters into various foreign currency exchange contracts with major financial institutions. 3. Liquidity risk The table below summarizes the maturity profile of the Company's financial liabilities based on contractual undiscounted payments: December 31, 2017 Less than one year 1 to 2 2 to 3 3 to 5 Total In thousands Trade payables $ 18,036 - - - $ 18,036 Other accounts payables 5,820 - - - 5,820 Long term loans and capital leases (including interest) 669 634 532 260 2,095 $ 24,525 $ 634 $ 532 $ 260 $ 25,951 December 31, 2016 Less than one year 1 to 2 2 to 3 3 to 5 Total In thousands Trade payables $ 16,277 - - - $ 16,277 Other accounts payables 5,614 - - - 5,614 Long term loan and capital leases (including interest) 464 461 429 549 1,903 $ 22,355 $ 461 $ 429 $ 549 $ 23,794 Changes in liabilities arising from financing activities January 1, 2017 Payments Foreign exchange movement Cash from new loans New leases December 31, 2017 In thousands Bank loans 1,673 (419 ) 177 279 - 1710 Capital leases 103 (111 ) - - 282 274 Total 1,776 (530 ) 177 279 282 1984 c. Fair value The following table demonstrates the carrying amount and fair value of the financial instruments presented in the financial statements not at fair value: Carrying Amount Fair Value December 31, December 31 , 2017 2016 2017 2016 In thousands Financial liabilities Bank loans and capital Leases $ 1,984 $ 1,776 $ 1,984 $ 1,761 The fair value of the bank loans and capital leases was based on standard pricing valuation model such as DCF which considers the present value of future cash flows discounted at the interest rate that reflects market conditions (Level 3). The carrying amount of cash and cash equivalents, short term bank deposits, trade and other receivables, trade and other payables approximates their fair value, due to the short term maturities of the financial instruments. d. Classification of financial instruments by fair value hierarchy Financial assets (liabilities) measured at fair value: Level 1 Level 2 In thousands December 31, 2017 Marketable securities at fair value through profit or loss: Equity shares $ 77 $ - Mutual funds 456 - Debt securities (corporate and government) 1,130 - Derivatives instruments - (8 ) Available for sale debt securities (corporate and government) - 8,597 $ 1,663 $ 8,589 Level 1 Level 2 In thousands December 31, 2016 Marketable securities at fair value through profit or loss: Equity shares $ 70 $ - Mutual funds 388 - Debt securities (corporate and government) 1,032 - Derivatives instruments - (32 ) Available for sale debt securities (corporate and government) - 9,164 $ 1,490 $ 9,132 During 2017 there was no transfer due to the fair value measurement of any financial instrument from Level 1 to Level 2, and furthermore, there were no transfers to or from Level 3 due to the fair value measurement of any financial instrument. December 31, 2017 2016 In thousands Sensitivity test to changes in market price of listed Securities Gain (loss) from change: 5% increase in market price $ 513 $ 535 5% decrease in market price $ (513 ) $ (535 ) Sensitivity test to changes in foreign currency: Gain (loss) from change: 5% increase in NIS $ (143 ) $ 19 5% decrease in NIS $ 143 $ (19 ) 5% increase in Euro $ (135 ) $ (184 ) 5% decrease in Euro $ 135 $ 184 Sensitivity tests and principal work assumptions The selected changes in the relevant risk variables were determined based on management's estimate as to reasonable possible changes in these risk variables. The Company has performed sensitivity tests of principal market risk factors that are liable to affect its reported operating results or financial position. The sensitivity tests present the profit or loss in respect of each financial instrument for the relevant risk variable chosen for that instrument as of each reporting date. The test of risk factors was determined based on the materiality of the exposure of the operating results or financial condition of each risk with reference to the functional currency and assuming that all the other variables are constant. e. Linkage terms of financial liabilities by groups of financial instruments pursuant to IAS 39: December 31, In thousands 2017 2016 In NIS: Bank loans and capital leases measured at amortized cost $ 1,984 $ 1,776 f. Derivatives and hedging: Derivatives instruments not designated as hedging The Company has foreign currency forward contracts designed to protect it from exposure to fluctuations in exchange rates, mainly of NIS and EUR, in respect of its transactions for debt from customers' debt, to service providers and inventory. Foreign currency forward contracts are not designated as cash flow hedges, fair value or net investment in a foreign operation. These derivatives are not considered as hedge accounting. As of December 31, 2017 the fair value of the derivative instruments not designated as hedging was a liability of $60 thousands. The open transactions for those derivatives were in an amount of $5.8 million. Cash flow hedges As of December 31, 2017, the Company held NIS/USD hedging contracts (cylinder contracts) designated as hedges of expected future The main terms of these positions were set to match the terms of the hedged items. As of December 31, 2017 the fair value of the derivative instruments designated as hedge accounting was an asset of $52 thousands. The open transactions for those derivatives were in an amount of $770 thousands.

EMPLOYEE BENEFIT LIABILITIES, N

EMPLOYEE BENEFIT LIABILITIES, NET	12 Months Ended
	Dec. 31, 2017
Disclosure of defined benefit plans [abstract]
EMPLOYEE BENEFIT LIABILITIES, NET	Note 16: - Employee Benefit Liabilities, NET Employee benefits consist of short-term benefits and post-employment benefits. a. Post-employment benefits: According to the labor laws and Severance Pay Law in Israel, the Company is required to pay compensation to an employee upon dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 to the Severance Pay Law, as specified below. The Company's liability is accounted for as a post-employment benefit only for employees not under Section 14. The computation of the Company's employee benefit liability is made in accordance with a valid employment contract or a collective employees agreement based on the employee's salary and employment term which establish the entitlement to receive the compensation. The post-employment employee benefits are normally financed by contributions classified as defined benefit plans, as detailed below: 1. Defined contribution deposit The Company’s agreements with part of its employees are in accordance with section 14 of the Israeli Severance Pay Law. Payments in accordance with Section 14 release the Company from any future severance liabilities in respect of those employees. The expenses for the defined benefit deposit in 2017, 2016 and 2015 were $ 884 thousands, $ 669 thousands and $702 thousands, respectively. 2. Defined benefit plans The Company accounts for the payment of compensation, as a defined benefit plan for which an employee benefit liability is recognized and for which the Company deposits amounts in a long-term employee benefit fund and in qualifying insurance policies. 3. Expenses recognized in comprehensive income (loss): Year Ended December 31, 2017 2016 2015 In thousands Current service cost $ 356 $ 359 $ 391 Interest expenses, net 23 20 18 Current service cost (income) due to the transfer of real yield from the compensation component to the royalties' component in executive insurance policies before 2004 (7 ) 5 (10 ) Total employee benefit expenses $ 372 $ 384 $ 399 Actual (negative) return on plan assets $ 119 $ 22 $ (12 ) The expenses are presented in the Statement of Comprehensive income (loss) as follows Year Ended December 31, 2017 2016 2015 In thousands Cost of revenues $ 211 $ 228 $ 209 Research and development 57 62 90 Selling and marketing 16 13 18 General and administrative 88 81 82 $ 372 $ 384 $ 399 4. The plan assets (liabilities), net: December 31, 2017 2016 In thousands Defined benefit obligation $ 5,907 $ 5,235 Fair value of plan assets 4,763 4,513 Total liabilities, net $ 1,144 $ 722 5 . Changes in the present value of defined benefit obligation 2017 2016 In thousands Balance at January 1, $ 5,235 $ 5,425 Interest costs 151 141 Current service cost 356 359 Benefits paid (641 ) (650 ) Demographic assumptions (28 ) (17 ) Financial assumptions 254 * Past Experience 6 (104 ) Currency Exchange 574 81 Balance at December 31, $ 5,907 $ 5,235 * Represent an amount of less than 1 thousands 6. Plan assets a) Plan assets Plan assets comprise assets held by a long-term employee benefit funds and qualifying insurance policies. b) Changes in the fair value of plan assets 2017 2016 In thousands Balance at January 1, $ 4,513 $ 4,638 Expected return 127 121 Contributions by employer 227 311 Benefits paid (586 ) (522 ) Demographic assumptions 1 1 Financial assumptions 1 - Past Experience (11 ) (100 ) Current service cost due to the transfer of real yield from the compensation component to the royalties component in executive insurance policies before 2004 7 (5 ) Currency exchange 484 69 Balance at December 31, $ 4,763 $ 4,513 7. The principal assumptions underlying the defined benefit plan 2017 2016 2015 % Discount rate of the plan liability 2.27 3.72 2.6 Future salary increases 4 4 4 The , . If the discount rate would be one percent higher (lower), the defined benefit obligation would decrease (increase) by $309 thousands ($380 thousands) if all other assumptions were held constant. If the expected salary growth would increase (decrease) by 1% the defined benefit obligation would increase (decrease) by $362 thousands ($298 thousands).

CONTINGENT LIABILITIES AND COMM

CONTINGENT LIABILITIES AND COMMITMENTS	12 Months Ended
	Dec. 31, 2017
Disclosure of contingent liabilities and commitments [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	Note 17: - Contingent Liabilities and commitments a. On August 23, 2010, the Company entered into 30 years collaboration agreement with Baxter Healthcare Corporation ("Baxter"), an international biopharmaceutical company, specializing, among other things, in the development, manufacture, marketing and sale of pharmaceutical products. During 2015, Baxter has assigned all its rights under the collaboration agreement to Baxalta US Inc. ("Baxalta") which was acquired in 2016 by Shire plc (“Shire” and in these consolidated financial statements Baxter, Baxalta and Shire will be referred to as "Shire"). The collaboration agreement consists of three main agreements (1) the appointment of Shire as the sole distributer of the Company's AAT IV drug ("Glassia") in the United States, Canada, Australia and New Zealand ("the Territory" and "the Distribution Agreement", respectively); (2) granting licenses to Shire for the use of the Company's knowhow and patents for the production, continued development and sale of Glassia According to the Raw Material Supply Agreement Shire undertook to provide the Company, free of charge, all the quantities of raw materials required by the Company for manufacturing Glassia to be sold to Shire for distribution by Shire in accordance with the Distribution Agreement. The Company recorded the fair value of the raw material used and sold as revenue and charged the same fair value to cost of revenue. In addition, Shire will provide raw material to the Company, for the development, production, sale and distribution of products by the Company . b. On August 2, 2012, the Company entered into a strategic agreement with CHIESI FARMACEUTICI S. P. A, a fully integrated European Pharmaceutical company focused on respiratory disease and special care products ("Chiesi"). According to the agreement, Chiesi was an exclusive distributor of the AAT inhaled product of the Company for treatment of alpha-1 antitrypsin deficiency ("Product") in Europe. As part of the Distribution Agreement, the Company was entitled to receive payments of up to $ 60 million, contingent of meeting regulatory and sales milestones. As of December 31, 2017, the Company had received a total of $9 million for the achievement of certain upfront payments in respect of the Distribution Agreement. Due to the Company's decision in June 2017 to withdraw the Marketing Authorization Application (MAA) for this product with the European Medicines Agency (EMA), the Company and CHIESI mutually agreed on November 14, 2017 to terminate the parties’ European distribution agreement related to Kamada’s inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). There are no financial implications related to the termination of this agreement. c. The Company has engaged in operating lease agreements for office and storage spaces. These agreements will expire in 2026. Minimum future lease fees for the office and storage spaces as of December 31, 2017 are as follows: In thousands Year 1 $ 590 Year 2 to 5 2,479 Year 6 and thereafter 2,541 $ 5,610 d. The Company has engaged in operating lease agreements for the vehicles in its possession. These agreements will expire between 2018 and 2020. Minimum future lease fees for the existing vehicles as of December 31, 2017 are as follows: In thousands Year 1 $ 443 Year 2 284 Year 3 95 $ 822 e. In November 2006, an agreement was signed between the Company and a third party on the matter of research and development collaboration. As part of the agreement, the Company was licensed to use developments made by the third party. Furthermore, the third party will provide the Company with devices for carrying out the clinical trials, free of charge. In the event that the development is successful, the Company will pay the third party royalties based on sales of the devices. This obligation on behalf of the Company to pay royalties shall expire either when the patents expire or 15 years from the first commercial sale, whichever comes last. On the date of the expiry of the royalty period, the license will become non-exclusive and the Company shall be entitled to use the rights granted to it pursuant to the agreement without paying royalties or any other compensation. In addition, the third party would pay royalties of the total net sales exceeding a certain sum, according to a mechanism set in the agreement, until the patent expires or until 15 years pass from the first date of sale, whichever is earlier. In February 2008, the parties signed an amendment to the agreement according to which the exclusive global license granted to the Company was expanded to two additional indications. It was also decided that sales to the additional indications would be added to the sales of the first two outlines covered by the original agreement. Royalties' payments will be according to the royalty model set in the original agreement. In addition, the parties signed a commercialization and supply agreement, which ensures long-term regular supply of the device at the basis of the collaboration and spare parts of this device. f. In August 2007, the Company entered into a long-term agreement with a multinational European company for the purchase of a raw material used for the development and manufacture of medicines at graded amounts and prices. In addition to the price paid by the Company for the raw material, the Company will pay the supplier an additional sum upon the sale of the product manufactured from the raw material in the territories set in the agreement, after receiving regulatory approvals. As of December 31, 2017, the regulatory approval was not yet received. h. In July 2011, the Company signed a strategic collaboration agreement with an international pharmaceutical company in the area of clinical development, marketing and sales in the United States of a post exposure prophylaxis product for the prevention of rabies in human beings. The product, KamRAB, is developed, manufactured and marketed by the Company in other countries. The phase 3 clinical trial was completed in December 2014 had met the trial’s primary endpoint. The Company submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in August 2016 and received the FDA approval for the product on August 2017. In October 2016 the parties entered into an amendment to the agreement with respect to the conduct of clinical trial for pediatric treatment of Rabies in the United States which was initiated on March 2017. The cost of the study is equally shared between the parties.

GUARANTEES AND CHARGES

GUARANTEES AND CHARGES	12 Months Ended
	Dec. 31, 2017
Disclosure of guarantees and charges [Abstract]
GUARANTEES AND CHARGES	Note 18: - Guarantees and charges 1. In order to guarantee the rental payments for an office in Rehovot and other obligations, the Company provided a bank guarantees in the amount of $ 246 thousands. 2. As collateral for the Company’s original loans amount of NIS 8,355 thousands, the Company has pledged the specific assets which were purchased with those loans.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2017
Disclosure of classes of share capital [abstract]
EQUITY	Note 19: - Equity a. share capital December 31, 2017 December 31, 2016 Authorized Outstanding Authorized Outstanding ordinary shares of NIS 1 par value 70,000,000 40,262,819 70,000,000 36,419,842 On August 2, 2017 the Company closed a public offering on NASDAQ of 3,333,334 shares at $4.50 per share. As part of the offering, the underwriters received a right to purchase an additional 500,000 ordinary shares to cover over-allotments at the same price per share. This option was fully exercise on August 30, 2017. The Company's total net proceeds from the issuance of the above shares were $15.6 million b. Rights attached to Shares Voting rights at the shareholders general meeting, rights to dividend, rights in case of liquidation of the Company and rights to nominate directors . c. Share options During 2017 and 2016, 10,659 and 8,398 share options, respectively, were exercised into 1,988 and 1,101 ordinary shares of NIS 1 par value each for consideration of $3 thousand and less than $1 thousands, respectively. For additional information regarding options and restricted shares granted to employees and management in 2017, refer to Note 20 below. d. Capital management in the Company The Company's goals in its capital management are to preserve capital ratios that will ensure stability and liquidity to support business activity and create maximum value for shareholders.

SHARE-BASED PAYMENT

SHARE-BASED PAYMENT	12 Months Ended
	Dec. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [abstract]
SHARE-BASED PAYMENT	Note 20: - Share-Based Payment On July 24, 2011, the Company's Board of Directors approved a new unlisted Options Plan ("2011 Option Plan "). In September 2016 the Company's Board of Directors approved an amendment to the plan and renamed it the Israeli Share Award Plan ("2011 Plan") to include restricted shares ("RS") awards (options and RS) that generally vest during a four-year period following the date of the grant in 13 installments: 25% of the options vest on the first anniversary of the grant date and 6.25% options vest at the end of each quarter thereafter. a. Expense recognized in the financial statements The share based payment expense that was recognized for services received from employees and directors is presented in the following table: For the Year Ended December 31 2017 2016 2015 In thousands Cost of revenues $ 179 $ 332 $ 564 Research and development 138 134 390 Selling and marketing 48 71 98 General and administrative 118 534 855 Total share-based payment $ 483 $ 1,071 $ 1,907 b. Option granted to the Company's Chief Executive Officer ("CEO") On November 30, 2017, the Company’s general shareholders meeting approved the grant of 18,000 options and 6,000 RSs to Mr. Amir London, the Company’s CEO. The RSs do not have exercise price. The options are exercisable into ordinary shares at an exercise price of NIS 21.99 per option. According to a calculation formula based on the binomial model, the fair value of the options was estimated at $26 thousands. The fair value of the RSs was estimated based on the market price of the shares on the grant date at $28 thousands. On August 30, 2016, the Company’s general shareholders meeting approved the grant of 18,000 options and 6,000 RSs to Mr. Amir London, the Company’s CEO. The RSs do not have exercise price. The options are exercisable into ordinary shares at an exercise price of NIS 15.2 per option. According to a calculation formula based on the binomial model, the fair value of the options was estimated at $41 thousands. The fair value of the RSs was estimated based on the market price of the shares on the grant date at $30 thousands. c. Employees options 1. During 2017, 2016 and 2015 the Company's Board of Directors approved the grant, of 405,950, 320,775 and 356,075 options, respectively to employees and management. The fair value of the options was estimated at $597 thousands, $548 thousands and $749 thousands, respectively. 2. During 2017, the Company's Board of Directors approved the grant of 52,835 RSs to the Company’s employees and management. The RSs do not have exercise price. The RSs are exercisable in 13 installments, 25% of the RSs vest on the first anniversary of the grant date and 6.25% vest at the end of each quarter thereafter into ordinary shares. The fair value of the RSs was estimated based on the market price of the share on the grant date at $238 thousands. d. Directors options 1. On November 30, 2017, the Company’s general shareholders meeting approved the grant of a total of 35,000 options to the Company’s board of directors. The options are exercisable into ordinary shares at an exercise price of NIS 21.99 per option. According to a calculation formula based on the Binomial Model, the fair value of the options was estimated at $51 thousands. 2. On August 30, 2016, the Company’s general shareholders meeting approved the grant of 50,000 options to the Company’s directors. The options are exercisable ordinary shares at an exercise price of NIS 15.2 per option. According to a calculation formula based on the Binomial Model, the fair value of the options was estimated at $114 thousands. f. For additional information regarding the exercise of options during 2017, refer to Note 21. Change of Awards during the Year The following table lists the number of share options, the weighted average exercise prices of share options and modification in employee and service provider option plans during the year: 2017 2016 2015 Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price In NIS In NIS In NIS Outstanding at beginning of year 2,487,236 35.20 2,281,493 38.96 2,396,891 37.98 Granted 458,950 21.10 401,275 15.17 504,075 18.28 Exercised (10,659 ) 18.19 (8,398 ) 18.47 (430,178 ) 11.18 Forfeited (363,155 ) 35.70 (187,134 ) 39.22 (189,295 ) 34.94 Outstanding at end of year 2,572,372 32.47 2,487,236 35.20 2,281,493 38.96 Exercisable at end of year 1,755,253 38.69 1,543,358 40.44 1,182,417 40.39 The weighted average remaining contractual life for the share options 3.22 3.62 4.15 The range of exercise prices for share options outstanding as of December 31, 2016 and 2017 were NIS 15- NIS 57. Exercise is either by cash consideration of the exercise price or by cashless method. The following table lists the number of RSs and modification in employee RSs during the year: Number of RSs 2017 2016 Outstanding at beginning of year 27,333 - Granted 58,835 29,333 End of restriction period (7,656 ) - Forfeited (2,000 ) (2,000 ) Outstanding at end of year 76,512 27,333 The weighted average remaining contractual life for the restricted share 5.92 6.20 Measurement of the fair value of equity-settled share options The Company uses the binomial model when estimating the grant date fair value of equity-settled share options. The measurement was made at the grant date of equity-settled share options since the options were granted to employees. The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan: 2017 2016 2015 Dividend yield (%) - - - Expected volatility of the share prices (%) 37-45 32-51 42-64 Risk-free interest rate (%) 0.1 – 1.83 0.13 – 1.83 0.07-2.04 Contractual term of up to (years) 6.5 6.5 6.5 Exercise multiple 2 2 2 Weighted average share prices (NIS) 16.05-16.44 15.17 17.17 Expected average forfeiture rate (%) 1-5 0-5 0-5

TAXES ON INCOME

TAXES ON INCOME	12 Months Ended
	Dec. 31, 2017
Disclosure of taxes on income [Abstract]
TAXES ON INCOME	NOTE 21: TAXES ON INCOME a. Tax laws applicable to the Company Law for the Encouragement of Industry (Taxes), 1969 The Law for the Encouragement of Industry (Taxes), 1969 (the “Encouragement of Industry Law”), provides several tax benefits for “Industrial Companies.” Pursuant to the Encouragement of Industry Law, a company qualifies as an Industrial Company if it is a resident of Israel and at least 90% of its income in any tax year (exclusive of income from certain defense loans) is generated from an “Industrial Enterprise” that it owns. An Industrial Enterprise is defined as an enterprise whose principal activity, in a given tax year, is industrial activity. An Industrial Company is entitled to certain tax benefits, including: (i) a deduction of the cost of purchases of patents, know-how and certain other intangible property rights (other than goodwill) used for the development or promotion of the Industrial Enterprise in equal amounts over a period of eight years, beginning from the year in which such rights were first used, (ii) the right to elect to file consolidated tax returns, under certain conditions, with additional Israeli Industrial Companies controlled by it, and (iii) the right to deduct expenses related to public offerings in equal amounts over a period of three years beginning from the year of the offering. Eligibility for benefits under the Encouragement of Industry Law is not contingent upon the approval of any governmental authority The Company believes that it currently qualifies as an industrial company within the definition of the Industry Encouragement Law. The Company cannot assure that the Israeli tax authorities will agree that the Company qualifies, or, if qualified, that it will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future. Law for the Encouragement of Capital Investments, 1959 Tax benefits prior to Amendment 60 The Company's facilities in Israel have been granted Approved Enterprise status under the Law for the Encouragement of Capital Investments, 1959, commonly referred to as the “Investment Law”. The Investment Law provides that capital investments in a production facility (or other eligible assets) may be designated as an Approved Enterprise. Until 2005, the designation required advance approval from the Investment Center of the Israel Ministry of Industry, Trade and Labor. Each certificate of approval for an Approved Enterprise ("certificate of approval") relates to a specific investment program, delineated both by the financial scope of the investment and by the physical characteristics of the facility or the asset. Under the Approved Enterprise programs, a company is eligible for governmental grants (“Grants Track”). Under the Grants Track the Company is eligible for investments grants awarded at various rates according to the development area in which the plant is located: in Development Zone A the rate is 24% and in Development Zone B the rate is 10%. In addition to the above grants, the Company is eligible to tax exemption at the first two years of the benefit period (as define below) and is subject to reduced corporate tax of 10% to 25% during the remaining five to eight years (depending on the extent of foreign investment in the Company) of the benefit period. The benefits period is limited to 12 years from completion of the investment or commencement of production ("Year of Operation"), or 14 years from the year in which the certificate of approval was obtained, whichever is earlier. The benefit period for part of the Company plants has ended, or up to 2017. Under the Investment Law a company may elect to receive an alternative package comprised of tax benefits (“Alternative Track”) instead of the above mentioned grants Track. Under the Alternative Track, a company’s undistributed income derived from an Approved Enterprise is exempt from corporate tax for an initial period of two to ten years (depending on the geographic location of the Approved Enterprise within Israel which begins in the first year that the Company realizes taxable income from the Approved Enterprise following the year of operation (as define below). After expiration of the initial tax exemption period, the Company is eligible for a reduced corporate tax rate of 10% to 25% for the following five to eight years, depending on the extent of foreign investment in the Company (as shown in the table below). The benefits period is limited to 12 years from the Year of Operation, or 14 years from the year in which the certificate of approval was obtained, whichever is earlier. Tax benefits under Amendment 60 On April 1, 2005, an amendment to the Investment Law came into effect (“Amendment 60”). The amendment revised the criteria for investments qualified to receive tax benefits. An eligible investment program under the amendment will qualify for benefits as a Privileged Enterprise (rather than the previous terminology of Approved Enterprise). Among other things, the amendment simplifies the approval process. In order to receive the tax benefits, the Amendment states that the company must make an investment in the Privileged Enterprise exceeding a certain percentage or a minimum amount specified in the Investments Law. Such investment may be made over a period of no more than three years ending at the end of the year in which the company requested to have the tax benefits apply to the Privileged Enterprise (the “Year of Election”). The Company received a Tax Ruling from the Israeli Tax Authority that its activity is an industrial activity and the Company will be eligible for the status of a Privileged Enterprise, provided that it meets the requirements under the ruling. The year of Election is 2009.The Company also obtained 2012 as a Year of election. The duration of tax benefits is subject to a limitation of the earlier of 7 to 10 years (depending on the extent of foreign investment in the company) from the first year in which the company generated taxable income (at, or after, the Year of Election) , or 12 years from the first day of the Year of Election. The amendment does not apply to investment programs approved prior to December 31, 2004. The new tax regime applies to new investment programs only. The tax benefits available under Approved Enterprise or Privileged Enterprise relate only to taxable income attributable to the specific Approved Enterprise or Privileged Enterprise, and the Company's effective tax rate will be the result of a weighted combination of the applicable rates. Tax Exemption Period Reduced Tax Period Rate of Reduced Tax Percent of Foreign Ownership 2 years 5 years 25% 0-25% 2 years 8 years 25% 25-49% 2 years 8 years 20% 49-74% 2 years 8 years 15% 74-90% 2 years 8 years 10% 90-100% The benefits available to an Approved Enterprise and a Privileged Enterprise are conditioned upon terms stipulated in the Investment Law and the related regulations and the criteria set forth in the applicable certificate of approval (for an Approved Enterprise). If the Company does not fulfill these conditions, in whole or in part, the benefits can be cancelled and we may be required to refund the amount of the benefits, linked to the Israeli consumer price index plus interest. The Company believes that its Approved Enterprise and Privileged Enterprise programs currently operate in compliance with all applicable conditions and criteria. If a company distributes dividends from tax-exempt income, the company will be taxed on the otherwise exempt income at the same reduced corporate tax rate that would have applied to that income. Distribution of dividends derived from income that was taxed at reduced rates, but not tax-exempt, does not result in additional tax consequences to the company. Shareholders who receive dividends derived from Approved Enterprise or Privileged Enterprise income are generally taxed at a rate of 15%, which is withheld and paid by the company paying the dividend, if the dividend is distributed during the benefits period or within the following 12 years (the limitation does not apply to a Foreign Investors Company, which is a company that more than 25% of its shares owned by non-Israeli residents). Preferred Enterprise Tax Benefits under the 2011 Amendment As of January 1, 2011 new legislation amending to the Investment Law came into effect (the “2011 Amendment”). The 2011 Amendment introduced a new status of “Preferred Company” and “Preferred Enterprise”, replacing the existed status of “Beneficiary Company” and “Beneficiary Enterprise”. Similarly to “Beneficiary Company”, a Preferred Company is an industrial company owning a Preferred Enterprise which meets certain conditions (including a minimum threshold of 25% export). However, under this new legislation the requirement for a minimum investment in productive assets was cancelled. Under the 2011 Amendment, a uniform corporate tax rate will apply to all qualifying income of the Preferred Company, as opposed to the former law, which was limited to income from the Approved Enterprises and Beneficiary Enterprise during the benefits period. The uniform corporate tax rate will be 12.5% elsewhere in Israel (in development area A - 7%). On August 5, 2013, the "Knesset" issued the Law for Changing National Priorities (Legislative Amendments for Achieving Budget Targets for 2013 and 2014), which consists of Amendment 71 to the Encouragement Law ("the Amendment"). According to the Amendment, the tax rate on preferred income from a preferred enterprise in 2014 and onwards will be 16% (in development area A - 9%). The Amendment also prescribes that any dividends distributed to individuals or foreign residents from the preferred enterprise's earnings as above will be subject to tax at a rate of 20% from 2014 and onwards (or a reduced rate under an applicable double tax treaty). Upon a distribution of a dividend to an Israeli company, no withholding tax is remitted. In December 2016, the "Knesset" amended the Investment Law. According to the amendment, effective from January 1, 2017 the tax rate on: 1. Preferred income from a preferred enterprise will be 16% (in development area A – 7.5% instead of 9%). 2. Preferred income resulting from IP in a preferred technology enterprise will be 12% (in development area A – 7.5%). 3. Preferred income resulting from IP in a special preferred technology enterprise will be 6%. 4. Any dividends distributed from technology enterprise earnings to a foreign company that qualifies the provisions that are detailed in the law, will be subject to tax at a rate of 4%. The Company has evaluated the effect of the adoption of the Amendment on its financial statements, and as of the date of the approval of the financial statements, the Company believes that it will not apply the Amendment. Accordingly, the Company has not adjusted its deferred tax balances as of December 31, 2016. The Company may change its position in the future. b. Tax rates applicable to the Company (other than the applicable preferred tax) In January 2016, the Law for Amending the Income Tax Ordinance (No. 216) (Reduction of Corporate Tax Rate), 2016 was approved, which includes a reduction of the corporate tax rate from 26.5% to 25%, effective from January 1, 2016. In December 2016, the Israeli Parliament's Plenum approved, as part of the economic efficiency law (Legislative Amendments for Achieving Budget Targets for 2017 and 2018), a reduction of the corporate tax rate in 2017 from 25% to 24%, and in 2018 from 25% to 23%. c. Tax assessments 1. Finalized tax assessments The Company has finalized its tax assessments through 2012. 2. Settlement of tax assessments On July 10, 2016, the Company and the Israel Tax Authority (ITA) entered into a settlement agreement for the tax years 2004-2006. As part of the agreement, the Company paid NIS 5 million ($ 1.3 million) (including interest and CPI adjustment). d. Carry forward losses for tax purposes and other temporary differences As of December 31, 2017, the Company has carry forward losses and other temporary differences in the amount of $ 90.1 million. e. Deferred taxes: The Company did not recognize deferred tax assets for carry forward losses and other temporary differences, because their utilization in the foreseeable future is not probable. f. Current taxes on income Year ended December 31, 2017 2016 2015 In thousands Current taxes $ 129 $ 362 $ - Taxes in respect of prior years 140 1,360 - $ 269 $ 1,722 $ - g. Theoretical tax: The reconciliation between the statutory tax rate and the effective tax rate as recorded in profit or loss, does not provide significant information and therefore was not presented.

SUPPLEMENTARY INFORMATION TO TH

SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF PROFIT AND LOSS	12 Months Ended
	Dec. 31, 2017
Disclosure of supplementary information to the statements of comprehensive loss [Abstract]
SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF PROFIT AND LOSS	Note 22: - Supplementary Information to the Statements of profit and loss Year Ended December 31, 2017 2016 2015 In thousands a. Additional information about revenues Revenues from major customers each of whom amount to 10% or more, of total revenues Customer A – Proprietary products Segment $ 60,383 $ 40,451 $ 26,032 Customer B – Proprietary products Segment and Distribution Segment - 10,225 10,306 $ 60,383 $ 50,676 $ 36,338 Revenues based on the location of the customers, are as follows: Year Ended December 31, 2017 2016 2015 In thousands U.S.A. $ 60,405 $ 40,585 $ 26,559 Israel 26,355 25,340 30,624 Europe 5,348 3,825 3,223 Latin America 5,248 4,221 6,036 Asia 4,979 3,028 2,900 Others 490 495 564 $ 102,825 $ 77,494 $ 69,906 Year Ended December 31, 2017 2016 2015 In thousands b. Cost of goods sold Cost of materials $ 41,179 $ 36,154 $ 38,848 Salary and related expenses 13,137 10,596 9,991 Depreciation and amortization 2,504 2,443 2,383 Energy 1,202 959 922 Subcontractors 3,995 2,833 2,112 Other manufacturing expenses 1,572 1,057 1,220 63,589 54,042 55,476 Decrease (increase) in inventories 7,148 2,092 (935 ) $ 70,737 $ 56,134 $ 54,541 c. Research and development Salary and related expenses $ 6,413 $ 5,237 $ 4,566 Subcontractors 3,392 8,318 8,002 Materials and allocation of facility costs 1,101 1,907 3,386 Others 1,067 783 576 $ 11,973 $ 16,245 $ 16,530 d. Selling and marketing Salary and related expenses $ 1,470 $ 1,272 $ 1,227 Marketing support 95 79 368 Packing, shipping and delivery 607 494 454 Marketing and advertising 627 337 560 Registration and marketing fees 1,162 796 794 Others 437 265 249 $ 4,398 $ 3,243 $ 3,652 Year Ended December 31, 2017 2016 2015 In thousands e. General and administrative Salary and related expenses $ 3,138 $ 3,029 $ 2,604 Employees welfare 2,182 1,465 1,391 Professional fees 1,497 1,378 1,482 Depreciation, amortization and impairment 649 712 524 Others 807 769 606 $ 8,273 $ 7,353 $ 6,607 f. Financial incomes and expenses Financial incomes Interest income $ 500 $ 469 $ 463 Financial expenses Interest and amortization from debentures $ - $ - $ 731 Fees and interest paid to financial institutions 162 126 111 Others - - 92 $ 162 $ 126 $ 934

INCOME (LOSS) PER SHARE

INCOME (LOSS) PER SHARE	12 Months Ended
	Dec. 31, 2017
Income (loss) per share attributable to equity holders of the Company:
INCOME (LOSS) PER SHARE	Note 23: - Income (Loss) per Share a. Details of the number of shares and income (loss) used in the computation of income (loss) per share Year Ended December 31 2017 2016 2015 Weighted Number of Shares Income Attributed to equity holders of the Company Weighted Number of Shares Loss Attributed to equity holders of the Company Weighted Number of Shares Loss Attributed to equity holders of the Company In thousands For the computation of basic income (loss) 37,970,697 $ 6,901 36,418,833 $ (6,733 ) 36,245,813 $ (11,270 ) Effect of potential dilutive ordinary shares 74,400 - - - - - For the computation of diluted income (loss) 38,045,097 $ 6,901 36,418,833 $ (6,733 ) 36,245,813 $ (11,270 ) b. The computation of the diluted income per share in 2017, did take into account the options and RSs due to their anti-dilutive effect.

OPERATING SEGMENTS

OPERATING SEGMENTS	12 Months Ended
	Dec. 31, 2017
Disclosure of operating segments [abstract]
OPERATING SEGMENTS	Note 24: - Operating Segments a. General The operating segments are identified on the basis of information that is reviewed by the chief operating decision maker ("CODM") to make decisions about resources to be allocated and assess its performance. Accordingly, for management purposes, the Group is organized into operating segments based on the products and services of the business units and has two operating segments as follows: Proprietary Products Develop and manufacture plasma-derived therapeutics and market them in more than 15 countries. Distribution Distribute imported drugs in Israel which are manufactured by third parties, most of which are produced from plasma or its derivative products. Segment performance is evaluated based on revenues and gross profit in the financial statements. The segment results reported to the CODM include items that are allocated directly to the segments and items that can be allocated on a reasonable basis. Items that were not allocated, mainly the Group's headquarter assets, general and administrative costs and financial costs (consisting of finance expenses and finance income and including fair value adjustments of financial instruments), are managed on a group basis. The segment liabilities do not include loans and financial liabilities as these liabilities are managed on a group basis. b. Reporting on operating segments Proprietary Products Distribution Total In thousands Year Ended December 31, 2017 Revenues $ 79,559 $ 23,266 $ 102,825 Gross profit $ 28,224 $ 3,864 $ 32,088 Unallocated corporate expenses (24,644 ) Finance expense, net (274 ) Income before taxes on income $ 7,170 Proprietary Products Distribution Total In thousands Year Ended December 31, 2016 Revenues $ 55,958 $ 21,536 $ 77,494 Gross profit $ 18,235 $ 3,125 $ 21,360 Unallocated corporate expenses (26,841 ) Finance income, net 470 Loss before taxes on income $ (5,011 ) Proprietary Products Distribution Total In thousands Year Ended December 31, 2015 Revenues $ 42,952 $ 26,954 $ 69,906 Gross profit $ 12,051 $ 3,314 $ 15,365 Unallocated corporate expenses (26,789 ) Finance income, net 154 Loss before taxes on income $ (11,270 )

BALANCES AND TRANSACTIONS WITH

BALANCES AND TRANSACTIONS WITH RELATED PARTIES	12 Months Ended
	Dec. 31, 2017
Disclosure of transactions between related parties [abstract]
BALANCES AND TRANSACTIONS WITH RELATED PARTIES	Note 25: - Balances and Transactions with Related Parties a. Balances with related parties December 31, 2017 December 31, 2016 In thousands December 31, 2017 Other accounts payables $ 292 $ 230 Employee benefit liabilities, net $ 92 $ 170 Trade receivable $ 2,382 $ 675 b. Benefits to related parties Year Ended December 31, 2017 2016 In thousands Salary and related expenses to those employed by the Company or on its behalf $ 460 $ 473 Salary of directors not employed by the Company or on its behalf $ 107 $ 122 Number of People to whom the Salary and Benefits Refer Related and related parties employed by the Company or on its behalf 2 2 Directors not employed by the Company 2 3 4 5 c. Benefits to key executive personnel (including non-related parties) Year Ended December 31, 2017 2016 2015 In thousands Short-term benefits $ 2,719 $ 2,453 $ 2,144 Share-based payment 310 460 650 Other long-term benefits 6 28 61 $ 3,035 $ 2,941 $ 2,855 d. Transactions with related parties Year Ended December 31, 2017 2016 2015 In thousands Sales $ 3,455 $ 2,230 $ 2,795 Selling and marketing expenses $ 121 $ 101 $ 114 General and administrative expenses $ 446 $ 503 $ 526 e. Revenues and Expenses from Related and Interested Parties Terms of Transactions with Related Parties 1. Sales to related parties are conducted at market prices. Balances that have yet to be repaid by the end of the year are not guaranteed, bear no interest and their settlement will be in cash. No guarantees were received or given for sums receivable or payable. For the years ended December 31, 2017, 2016 and 2015, the Company recorded no allowance for doubtful accounts for sums receivable from related parties. 2. On May 26, 2011, the Company announced its engagement in an amended agreement regarding the distribution of Glassia, that revises and replaces the distribution agreement signed in 2001 between the Company and Tuteur SACIFIA ("Tuteur"), a company registered in Argentina, currently under the control of the Hahn family. The amendment to the agreement was made as an arm’s length transaction. On August 19, 2014 the Company amended the agreement in order to add KamRho(D) as an additional product to be distributed by Tuteur and expanded the territory to include Bolivia. Pursuant to the distribution agreement, Tuteur serves as the exclusive distributor of Glassia and KamRho(D), in Argentina, Paraguay and Bolivia. In 2016 the board of directors approved to provide Tuteur reimbursement at a non-material amount to be used for marketing activities aimed to locating new AATD patients and increasing the overall number of AATD patients treated with Glassia in Argentina. Such reimbursement will be granted until the end of September 2019. In 2016 and 2017 a reimbursement was paid according to the agreement. In addition, in 2016 and in 2017 the board of directors also approved to grant Tuteur an arm’s length discount for KamRho(D) at a non-material amount. 3. Mr. Reuven Behar, a partner of Fischer Behar Chen Well Orion Co., the Company’s external legal counsel was a director in the Company until May 2016. Fees attributed to Fischer Behar Chen Well Orion Co. are included in the tables above for the period ending May 1, 2016. On July 29, 2015 the Company’s Board of Directors approved to engage Khairi S.A. (“Khairi”), a company that is held, inter alia, by Mr. Leon Recanati, the Chairman of the Company's board of directors, Mr. Jonathan Hahn, a director in the company and his siblings and Mr. Reuven Behar, a former director in the Company, who serves as the chairman of the board of directors of Khairi, in a distribution agreement, for the distribution of Glassia and KamRho(D) in Uruguay. This distribution agreement with Khairi is an arm’s length transaction. f. Chief executive officer employment terms On June 30, 2015 the Company’s shareholders approved the employment terms of Mr. Amir London in his position as the Company’s chief executive officer (“CEO”), effective as of July 1, 2015. Under the employment agreement, Mr. Amir London is entitled to a monthly gross salary of NIS 65,000 (or $16,658). On August 30, 2016 the general meeting of the shareholders approved the update of Mr. London’s monthly gross salary to NIS 71,500 (or $18,430), effective as of July, 1 2016. During 2017 the Company recorded approximately $127 thousands, as a bonus to Mr. London. As for the grant of options and restricted shares to Mr. London, refer to Note 20b.

SIGNIFICANT ACCOUNTING POLICI31

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2017
Disclosure of significant accounting policies [Abstract]
Basis of presentation of financial statements	a. Basis of presentation of financial statements 1. These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Board. 2. Measurement basis: The Company's consolidated Financial Statements are prepared on a cost basis, except for financial instruments (including derivatives) at fair value through profit or loss and other comprehensive income such as available for sales financial assets, employee benefit assets and employee benefit liabilities. The Company has elected to present profit or loss items using the "function of expense" method. b . The Company's operating cycle is one year. c. The consolidated financial statements comprise the financial statements of companies that are controlled by the Company (subsidiaries). Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. The consolidation of the financial statements commences on the date on which control is obtained and ends when such control ceases. The financial statements of the Company and of the subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group. Significant intercompany balances and transactions and gains or losses resulting from intercompany transactions are eliminated in full in the consolidated financial statements.
Functional currency, presentation currency and foreign currency	d. Functional currency, presentation currency and foreign currency 1. Functional currency and presentation currency The consolidated financial statements are presented in U.S. dollars, which is the Company's functional and presentation currency. 2. Transactions, assets and liabilities in foreign currency Transactions denominated in foreign currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost in a foreign currency are translated at the exchange rate at the date of the transaction.
Cash equivalents	e. Cash equivalents Cash equivalents are considered as highly liquid investments, including unrestricted short-term bank deposits with an original maturity of three months or less from the date of purchase.
Short-term investments	f. Short-term investments: Short-term bank deposits with a maturity of more than three months from the deposit date but less than one year, available for sale financial investments (debentures) and financial assets held for trading at fair value through profit or loss (debentures and stocks).
Allowance for doubtful accounts	g. Allowance for doubtful accounts The allowance for doubtful accounts is determined in respect of specific debts whose collection, in the opinion of the Company's management, is doubtful. Impaired debts are derecognized when they are assessed as uncollectible. As of December 31, 2017 there was no allowance for doubtful accounts and as of December 31, 2016, the balance of allowance for doubtful accounts was $399 thousands.
Inventory	h. Inventories Inventories are measured at the lower of cost and net realizable value. The cost of inventories comprises costs of purchase of raw and other materials and costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business. Cost of inventories is determined as follows: Raw materials - At cost using the first-in, first-out method. Work in process - Direct costs and indirect costs calculated at average costs for the quarter of manufacturing including materials, labor and other direct and indirect manufacturing costs on the basis of each batch. Finished products - Direct costs and indirect costs calculated at average costs for quarter of manufacturing including materials, labor and other direct and indirect manufacturing costs on the basis of each batch. Purchased products - At cost on a "first in – first out" basis. The Company periodically evaluates the condition and age of inventories and accounts for impairment of inventories with a lower market value or which are slow moving. Research and development costs Research expenditures are recognized in profit or loss when incurred. An intangible asset arising from a development project or from the development phase of an internal project is recognized if the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale; the Company's intention to complete the intangible asset and use or sell it; the Company's ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; the availability of adequate technical, financial and other resources to complete the intangible asset; and the Company's ability to measure reliably the expenditure attributable to the intangible asset during its development. Since the Company development projects are often subject to regulatory approval procedures and other uncertainties, the conditions for the capitalization of costs incurred before receipt of approvals are not normally satisfied and therefore, development expenditures are recognized in profit or loss when incurred
Revenue recognition	i . Revenue recognition Revenues are recognized in profit or loss when the revenues can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the Company and the costs incurred or to be incurred in respect of the transaction can be measured reliably. In cases where the Company operates as a principal supplier and it exposed to the risks and rewards associated with the transaction, revenues are presented on a gross basis. Revenues are measured at the fair value of the consideration received less any trade discounts, volume rebates and returns. The specific criteria for revenue recognition for the following types of revenues are: - Revenues from the sale of goods are recognized when all the significant risks and rewards of ownership of the goods have passed to the buyer and the seller no longer retains continuing managerial involvement. The delivery date is usually the date on which ownership passes. - Agreements with multiple elements provide for varying consideration terms, such as upfront payments and milestone payments. Revenues from such agreements that do not contain a general right of return and that are composed of multiple elements such as distribution exclusivity, license and services are allocated to the different elements and are recognized in respect of each element separately. An element constitutes a separate accounting unit if and only if it has a separate value to the customer. Revenue from the different element is recognized when the criteria for revenue recognition have been met and only to the extent of the consideration that is not contingent upon completion or performance of future services in the contract. Revenue from milestone and upfront events stipulated in the agreements is recognized upon the occurrence of a substantive element specified in the agreement or as a measure of substantive progress towards completion. In events that the Company receives at no charge raw material, that is required for manufacturing one of the Company's products, the Company recorded the fair value of the raw material used and sold as revenue and charged the same fair value to cost of revenue. Deferred revenues Deferred revenues include unearned amounts received from customers not yet recognized as revenues.
Taxes on income	j. Taxes on income Taxes on income in profit or loss comprise current and deferred taxes. Current or deferred taxes are recognized in profit or loss, except to the extent that the tax arises from items which are recognized directly in other comprehensive income or in equity. 1. Current taxes: The current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the end of reporting period as well as adjustments required in connection with the tax liability in respect of previous years. 2. Deferred taxes: Deferred taxes are computed in respect of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes. Deferred taxes are measured at the tax rates that are expected to apply when the asset is realized or the liability is settled, based on tax laws that have been enacted or substantively enacted by the end of the reporting period. Deferred tax assets are reviewed at the end of each reporting period and reduced to the extent that it is not probable that they will be utilized. Temporary differences for which deferred tax assets had not been recognized are reviewed at the end of each reporting period and a respective deferred tax asset is recognized to the extent that their utilization is probable. Deferred taxes are offset in the statement of financial position if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority.
Leases	k. Leases The Group as lessee: 1. Finance lease Finance leases transfer to the Company substantially all the risks and benefits incidental to ownership of the leased asset. At the commencement of the lease term, the leased assets are measured at the fair value of the leased asset or, if lower, at the present value of the minimum lease payments. The leased asset is depreciated over the shorter of the lease term and the expected life of the leased asset. 2. Operating lease Lease agreements are classified as an operating lease if they do not transfer substantially all the risks and benefits incidental to ownership of the leased asset. Lease payments are recognized as an expense in profit or loss on a straight-line basis over the lease term.
Property, plant and equipment	l. Property, plant and equipment Property, plant and equipment are measured at cost, including directly attributable costs and financing costs, less accumulated depreciation, accumulated impairment losses and any related investment grants and excluding day-to-day servicing expenses. Cost includes spare parts and auxiliary equipment that can be used only in connection with the plant and equipment. The Company's assets include computer systems comprising hardware and software. Software forming an integral part of the hardware to the extent that the hardware cannot function without the programs installed on it is classified as property, plant and equipment. In contrast, software that adds functionality to the hardware is classified as an intangible asset. The cost of assets includes the cost of materials, direct labor costs, as well as any costs directly attributable to bringing the asset to the location and condition necessary for it to operate in the manner intended by management. Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Mainly Buildings 2.5-4 4 Machinery and equipment 10-20 15 Vehicles 15 15 Computers, software, equipment and office furniture 6-33 33 Leasehold improvements (* ) 10 (*) Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement. The useful life, depreciation method and residual value of an asset are reviewed at the year-end and any changes are accounted for prospectively as a change in accounting estimate. Depreciation of an asset ceases at the earlier of the date that the asset is classified as held for sale and the date that the asset is derecognized.
Impairment of non-financial assets	m. Impairment of non-financial assets The Company evaluates the need to record an impairment of the carrying amount of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable. If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. An impairment loss of an asset, is reversed only if there have been changes in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognized. Reversal of an impairment loss, as above, shall not be increased above the lower of the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized for the asset in prior years and its recoverable amount.
Financial instruments	n. Financial instruments 1. Financial assets Financial assets within the scope of IAS 39 are initially recognized at fair value plus directly attributable transaction costs, except for financial assets measured at fair value through profit or loss. After initial recognition, the accounting treatment of financial assets is based on their classification as follows: a. Financial assets at fair value through profit or loss Financial assets held for trading and derivative instruments that do not qualify for hedge accounting. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in the near term. b. Receivables The Company has receivables that are financial assets with fixed or determinable payments that are not quoted in an active market. c. Available for sale ("AFS") financial investments AFS financial investments include debt securities. Debt securities in this category are those that are intended to be held for an indefinite period of time and that may be sold in response to needs for liquidity or in response to changes in the market conditions. The Company has classified all marketable securities as short-term, even though the stated maturity date may be one year or more beyond the current balance sheet date, because it may sell these securities prior to maturity to meet liquidity needs or as part of risk versus reward objectives. After initial measurement, AFS financial investments are subsequently measured at fair value with unrealized gains and losses recognized in other comprehensive income ("OCI") until the investment is derecognized For AFS financial investments, the Company assesses at each reporting date whether there is objective evidence that an investment is impaired. For debt instruments classified as AFS financial assets, objective evidence of impairment may arise as a result of one or more events that have a negative impact on the estimated future cash flows of the asset since the recognition of the asset. Where there is evidence of impairment, the cumulative loss - measured as the difference between the acquisition cost and the fair value - is reclassified from other comprehensive income and recognized as an impairment loss in profit or loss. In a subsequent period, the amount of the impairment loss is reversed if the increase in fair value can be related objectively to an event occurring after the impairment was recognized. The amount of the reversal, up to the amount of any previous impairment, is recorded in profit or loss. 2. Financial liabilities Financial liabilities within the scope of IAS 39 are initially measured at fair value. After initial recognition, the accounting treatment of financial liabilities is based on their classification as follows: a. Financial liabilities measured at amortized cost Loans, including capital leases, are measured based on their terms at amortized cost using the effective interest method taking into account directly attributable transaction costs. b. Financial liabilities measured at fair value Derivatives, including separated embedded derivatives, are classified as held for trading unless they are designated as effective hedging instruments. 3. Fair value Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: - Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities. - Level 2 - inputs other than quoted prices included within Level 1 that are observable either directly or indirectly. - Level 3 - inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data). 4. Offsetting financial instruments Financial assets and financial liabilities are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously. The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that will cause the right to expire. 5. De-recognition of financial instruments a. Financial assets A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire or the Company has transferred its contractual rights to receive cash flows from the financial asset or assumes an obligation to pay the cash flows in full without material delay to a third party and has transferred substantially all the risks and rewards of the asset, or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset. b. Financial liabilities A financial liability is derecognized when it is extinguished, that is when the obligation is discharged or cancelled or expires. A financial liability is extinguished when the debtor (the Company) discharges the liability by paying in cash, other financial assets, goods or services or is legally released from the liability.
Derivative financial instruments designated as hedges	o. Derivative financial instruments designated as hedges The Company enters into contracts for derivative financial instruments such as forward currency contracts and cylinder strategy in respect of foreign currency to hedge risks associated with foreign exchange rates fluctuations. Such derivative financial instruments are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. At the inception of a hedge relationship, the Company formally designates and documents the hedge relationship to which the Company wishes to apply hedge accounting and the risk management objective and strategy for undertaking the hedge. The hedge effectiveness is assessed at the end of each reporting period. Cash flow hedges The effective portion of the gain or loss on the hedging instrument is recognized as other comprehensive income (loss), while any ineffective portion is recognized immediately in profit or loss. Amounts recognized as other comprehensive income (loss) are reclassified to profit or loss when the hedged transaction affects profit or loss, such as when the hedged income or expense is recognized or when a forecast payment occurs. If the forecast transaction or firm commitment is no longer expected to occur, amounts previously recognized in equity are reclassified to profit or loss. If the hedging instrument expires or is sold, terminated or exercised, or if its designation as a hedge is revoked, amounts previously recognized in equity remain in equity until the forecast transaction or firm commitment occurs.
Accrued expenses	p . Accrued expenses A provision in accordance with IAS 37 is recognized when the Group has a present (legal or constructive) obligation as a result of a past event, it is expected to require the use of economic resources to clear the obligation and a reliable estimate can be made of it.
Employee benefit liabilities	r. Employee benefit liabilities The Company has several employee benefit plans: 1. Short-term employee benefits Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made. 2. Post-employment benefits The post-employment benefits plans are normally financed by contributions to insurance companies and classified as defined contribution plans or as defined benefit plans. The Company has defined contribution plans pursuant to Section 14 to the Israeli Severance Pay Law under which the Company pays fixed contributions to certain employees under section 14 and will have no legal or constructive obligation to pay further contributions. Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed concurrently with performance of the employee's services. In addition the Company operates a defined benefit plan in respect of severance pay pursuant to the Israeli Severance Pay Law. According to the Law, employees are entitled to severance pay upon dismissal or retirement. The liability for termination of employment is measured using the projected unit credit method. The amounts are presented based on discounted expected future cash flows using a discount rate determined by reference to market yields at the reporting date on high quality corporate bonds that are linked to the Consumer Price Index with a term that is consistent with the estimated term of the severance pay obligation. In respect of its severance pay obligation to certain of its employees, the Company makes current deposits in pension funds and insurance companies ("the plan assets"). Plan assets comprise assets held by a long-term employee benefit fund or qualifying insurance policies. Plan assets are not available to the Company's own creditors and cannot be returned directly to the Company. The liability for employee benefits shown in the statement of financial position reflects the present value of the defined benefit obligation less the fair value of the plan assets. Re-measurements of the net liability are recognized in other comprehensive income in the period in which they occur.
Share-based payment transactions	q. Share-based payment transactions The Company's employees and other service providers are entitled to remuneration in the form of equity-settled share-based payment transactions. Equity-settled transactions The cost of equity-settled transactions (options and restricted shares) with employees is measured at the fair value of the equity instruments granted at grant date. The fair value of options is determined using a standard option pricing model. The fair value of restricted shares is determined using the share price at the grant date. As for other service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments. In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, they are measured by reference to the fair value of the equity instruments granted. The cost of equity-settled transactions is recognized in profit or loss together with a corresponding increase in shareholder's equity during the period which the performance and/or service conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award ("the vesting period"). The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for awards that do not ultimately vest. If the Company modifies the conditions on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date.
Income (loss) per Share	r. Income (loss) per Share Income (loss) per share is calculated by dividing the income (loss) attributable to Company shareholders by the weighted number of outstanding ordinary shares during the period. Ordinary shares underlying shares options or restricted Shares are only included in the calculation of diluted income (loss) per share when their impact dilutes the income (loss) per share. Furthermore, potential ordinary shares converted during the period are included under diluted income (loss) per share only until the conversion date, and from that date on are included under basic income (loss) per share.
Reclassification of prior years' amounts	s. Reclassification of prior years' amounts Certain amounts in prior years' financial statements have been reclassified to conform to the current year's presentation. The reclassification had no effect on previously reported net loss or shareholders' equity.

SIGNIFICANT ACCOUNTING POLICI32

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of significant accounting policies [Abstract]
Schedule of Useful Lives for Property, Plant and Equipment	Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Mainly Buildings 2.5-4 4 Machinery and equipment 10-20 15 Vehicles 15 15 Computers, software, equipment and office furniture 6-33 33 Leasehold improvements (* ) 10

CASH AND CASH EQUIVALENTS (Tabl

CASH AND CASH EQUIVALENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Cash and cash equivalents [abstract]
Schedule of Cash and Cash Equivalents	December 31, 2017 2016 In thousands Cash and deposits for immediate withdrawal $ 8,539 $ 7,891 Cash equivalents in USD deposits (1) 4,001 2,001 Cash equivalents in NIS deposits (2) 141 76 $ 12,681 $ 9,968 (1) The deposits bear interest of 1.53% and 1.12% per year, as of December 31, 2017 and 2016, respectively. (2) The deposits bear interest of 0.01% per year, as of each December 31, 2017 and 2016.

SHORT-TERM INVESTMENTS (Tables)

SHORT-TERM INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of short-term investments [Abstract]
Schedule of Short-term Investments	December 31, 2017 2016 In thousands Marketable securities (equity and debt) at fair value through profit or loss $ 1,663 $ 1,490 Bank deposits in USD (1) 20,078 8,010 Available for sale debt securities 8,597 9,164 $ 30,338 $ 18,664 (1) The deposits bear interest of 1.70%-2.3% and 1.69 %

TRADE RECEIVABLES, NET (Tables)

TRADE RECEIVABLES, NET (Tables)	12 Months Ended
	Dec. 31, 2017
Trade and other current receivables [abstract]
Schedule of Trade Receivables, Net	December 31, 2017 2016 In thousands Open accounts: In NIS $ 8,263 $ 9,326 In USD 22,284 10,816 30,547 20,142 Checks receivable 115 45 30,662 20,187 Less allowance for doubtful accounts (1) - (399 ) Trade receivables, net $ 30,662 $ 19,788
Schedule of Allowance for Doubtful Accounts	Allowance for doubtful accounts: December 31, 2016 $ (399 ) Bad debt recognition 399 December 31, 2017 $ -
Schedule of Analysis of Past Due but Not Impaired Trade Receivables	An analysis of past due but not impaired trade receivables with reference to reporting date: Past due trade receivables with aging of Neither past due nor impaired Up to 30 Days 30-60 Days 60-90 Days 90-120 Days Over 120 days Total In thousands December 31, 2017 $ 29,692 680 $ 21 $ 152 $ 2 $ - $ 30,547 December 31, 2016 $ 17,769 1,891 $ 24 $ 43 $ 6 $ 10 $ 19,743

OTHER ACCOUNTS RECEIVABLES (Tab

OTHER ACCOUNTS RECEIVABLES (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of other accounts receivables [Abstract]
Schedule of Other Accounts Receivables	December 31, 2017 2016 In thousands Materials for clinical trials and inventory designated for R&D activities $ 635 $ 1,229 Prepaid expenses 822 1,057 Government authorities 563 374 Accrued interest 66 82 Other 46 321 $ 2,132 $ 3,063

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2017
Classes of current inventories [abstract]
Schedule of Inventories	December 31, 2017 2016 In thousands Finished products $ 5,168 $ 6,542 Purchased products 2,695 5,607 Work in progress 6,159 6,227 Raw materials 7,048 7,218 $ 21,070 $ 25,594 (1) During the years 2017, 2016 and 2015, the Company recognized, at cost of revenues, as impairment for inventories carried at net realizable value totaled of $460 thousands, $544 thousands and $470 thousands, respectively.

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of Composition and Movement of Property, Plant and Equipment	Composition and movement: 2017 Land and Buildings(1) Machinery and Equipment (1) (2) Vehicles Computers, Software, Equipment and Office Furniture Leasehold Improvements Total In thousands Cost Balance at January 1, 2017 $ 27,618 $ 26,485 $ 94 $ 5,520 $ 1,052 $ 60,769 Additions 781 3,151 - 1,002 1,196 6,130 Sale and write-off - (34 ) (28 ) - (975 ) (1,037 ) Balance as of December 31, 2017 28,399 29,602 66 6,522 1,273 65,862 Accumulated Depreciation Balance as of January 1, 2017 12,606 19,972 86 4,559 967 38,190 Depreciation and impairment 1,310 1,492 1 635 85 3,523 Sale and write-off - (34 ) (28 ) - (967 ) (1,029 ) Balance as of December 31, 2017 13,916 21,430 59 5,194 85 40,684 Depreciated cost as of December 31, 2017 $ 14,483 $ 8,172 $ 7 1,328 $ 1,188 $ 25,178 2016 Land and Buildings(1) Machinery and Equipment (1) (2) Vehicles Computers, Software, Equipment and Office Furniture Leasehold Improvements Total In thousands Cost Balance at January 1, 2016 $ 26,701 $ 24,111 $ 94 $ 5,156 $ 1,079 $ 57,141 Additions 963 3,220 - 507 62 4,752 Sale and write-off (46 ) (846 ) (143 ) (89 ) (1,124 ) Balance as of December 31, 2016 27,618 26,485 94 5,520 1,052 60,769 Accumulated Depreciation Balance as of January 1, 2016 11,237 19,310 83 4,136 1,012 35,778 Depreciation and impairment 1,402 1,355 3 564 44 3,368 Sale and write-off (33 ) (693 ) (141 ) (89 ) (956 ) Balance as of December 31, 2016 12,606 19,972 86 4,559 967 38,190 Depreciated cost as of December 31, 2016 $ 15,012 $ 6,513 $ 8 961 $ 85 $ 22,579 (1) Including labor costs charged in 2017 and 2016 to the cost of facilities, machinery and equipment in the amount of $431 thousands and $510 thousands, respectively. (2) Including financing costs of $44 thousands and $11 thousands capitalized in 2017 and 2016 respectively, to the cost of machinery and equipment.
Schedule of Capitalized Leasing Rights of Land from Israel Land Administration	Capitalized leasing rights of land from the Israel land administration. December 31, 2017 2016 In thousands Under finance lease $ 1,016 $ 1,029

OTHER LONG TERM ASSETS (Tables)

OTHER LONG TERM ASSETS (Tables)	12 Months Ended
	Dec. 31, 2017
Miscellaneous non-current assets [abstract]
Schedule of Other Long Term Assets	December 31, 2017 2016 In thousands Long term pre-paid expenses $ 49 $ 40

TRADE PAYABLES (Tables)

TRADE PAYABLES (Tables)	12 Months Ended
	Dec. 31, 2017
Trade and other current payables [abstract]
Schedule of Trade Payables	December 31, 2017 2016 In thousands Open debts mainly in USD $ 11,246 $ 11,187 Open debts in NIS 6,789 5,038 18,035 16,225 Notes payable 1 52 $ 18,036 $ 16,277

OTHER ACCOUNTS PAYABLES (Tables

OTHER ACCOUNTS PAYABLES (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of other accounts payable [Abstract]
Schedule of Other Accounts Payables	December 31, 2017 2016 In thousands Employees and payroll accruals $ 4,735 $ 4,135 Derivatives financial instruments 8 32 Accrued Expenses and Others 1,077 1,447 $ 5,820 $ 5,614

LOANS AND CAPITAL LEASES (Table

LOANS AND CAPITAL LEASES (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of loans and capital leases [abstract]
Schedule of Loans and Capital Leases	December 31, 2017 2016 In thousands Total loans and capital leases (1) 1,984 1,776 Less current maturities 614 412 Long term loans and capital leases $ 1,370 $ 1,364 (1) The capital lease balance was $274 thousands and $103 thousands, as of December 31, 2017 and 2016, respectively.

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about financial instruments [abstract]
Schedule of Classification of Financial Assets and Liabilities	The financial assets and financial liabilities in the balance sheet are classified by groups of financial instruments in pursuant to IAS 39: December 31, 2017 2016 In thousands Financial assets Financial assets at fair value through profit or loss: Marketable securities (equity and debt) $ 1,663 $ 1,490 Financial assets at fair value through other comprehensive income (loss)- Available for sale 8,597 9,164 Financial assets at cost: Cash 8,539 7,891 Short term bank deposits 24,220 10,087 $ 43,019 $ 28,632 Financial liabilities Financial liabilities at fair value: Derivatives instruments $ 8 $ 32 Financial liabilities measured at amortized cost: Bank loans and capital leases 1,984 1,776 $ 1,992 $ 1,808
Schedule of Maturity Profile of Company's Financial Liabilities based on Contractual Undiscounted Payments	The table below summarizes the maturity profile of the Company's financial liabilities based on contractual undiscounted payments: December 31, 2017 Less than one year 1 to 2 2 to 3 3 to 5 Total In thousands Trade payables $ 18,036 - - - $ 18,036 Other accounts payables 5,820 - - - 5,820 Long term loans and capital leases (including interest) 669 634 532 260 2,095 $ 24,525 $ 634 $ 532 $ 260 $ 25,951 December 31, 2016 Less than one year 1 to 2 2 to 3 3 to 5 Total In thousands Trade payables $ 16,277 - - - $ 16,277 Other accounts payables 5,614 - - - 5,614 Long term loan and capital leases (including interest) 464 461 429 549 1,903 $ 22,355 $ 461 $ 429 $ 549 $ 23,794
Schedule of Changes in Liabilities Arising From Financing Activities	Changes in liabilities arising from financing activities January 1, 2017 Payments Foreign exchange movement Cash from new loans New leases December 31, 2017 In thousands Bank loans 1,673 (419 ) 177 279 - 1710 Capital leases 103 (111 ) - - 282 274 Total 1,776 (530 ) 177 279 282 1984
Schedule of Carrying Amount and Fair Value of Financial Instruments	The following table demonstrates the carrying amount and fair value of the financial instruments presented in the financial statements not at fair value: Carrying Amount Fair Value December 31, December 31 , 2017 2016 2017 2016 In thousands Financial liabilities Bank loans and capital Leases $ 1,984 $ 1,776 $ 1,984 $ 1,761
Schedule of Financial Liabilities Measured at Fair Value	Financial assets (liabilities) measured at fair value: Level 1 Level 2 In thousands December 31, 2017 Marketable securities at fair value through profit or loss: Equity shares $ 77 $ - Mutual funds 456 - Debt securities (corporate and government) 1,130 - Derivatives instruments - (8 ) Available for sale debt securities (corporate and government) - 8,597 $ 1,663 $ 8,589 Level 1 Level 2 In thousands December 31, 2016 Marketable securities at fair value through profit or loss: Equity shares $ 70 $ - Mutual funds 388 - Debt securities (corporate and government) 1,032 - Derivatives instruments - (32 ) Available for sale debt securities (corporate and government) - 9,164 $ 1,490 $ 9,132
Schedule of Sensitivity Analysis for Market Risks	During 2017 there was no transfer due to the fair value measurement of any financial instrument from Level 1 to Level 2, and furthermore, there were no transfers to or from Level 3 due to the fair value measurement of any financial instrument. December 31, 2017 2016 In thousands Sensitivity test to changes in market price of listed Securities Gain (loss) from change: 5% increase in market price $ 513 $ 535 5% decrease in market price $ (513 ) $ (535 ) Sensitivity test to changes in foreign currency: Gain (loss) from change: 5% increase in NIS $ (143 ) $ 19 5% decrease in NIS $ 143 $ (19 ) 5% increase in Euro $ (135 ) $ (184 ) 5% decrease in Euro $ 135 $ 184
Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments	Linkage terms of financial liabilities by groups of financial instruments pursuant to IAS 39: December 31, In thousands 2017 2016 In NIS: Bank loans and capital leases measured at amortized cost $ 1,984 $ 1,776

EMPLOYEE BENEFIT LIABILITIES,44

EMPLOYEE BENEFIT LIABILITIES, NET (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of defined benefit plans [abstract]
Schedule of Expenses Recognized in Comprehensive Income (Loss)	Expenses recognized in comprehensive income (loss): Year Ended December 31, 2017 2016 2015 In thousands Current service cost $ 356 $ 359 $ 391 Interest expenses, net 23 20 18 Current service cost (income) due to the transfer of real yield from the compensation component to the royalties' component in executive insurance policies before 2004 (7 ) 5 (10 ) Total employee benefit expenses $ 372 $ 384 $ 399 Actual (negative) return on plan assets $ 119 $ 22 $ (12 )
Schedule of Expenses Presented in Statement of Comprehensive Income (Loss)	The expenses are presented in the Statement of Comprehensive income (loss) as follows Year Ended December 31, 2017 2016 2015 In thousands Cost of revenues $ 211 $ 228 $ 209 Research and development 57 62 90 Selling and marketing 16 13 18 General and administrative 88 81 82 $ 372 $ 384 $ 399
Schedule of Plan Assets (Liabilities), Net	The plan assets (liabilities), net: December 31, 2017 2016 In thousands Defined benefit obligation $ 5,907 $ 5,235 Fair value of plan assets 4,763 4,513 Total liabilities, net $ 1,144 $ 722
Schedule of Changes in Present Value of Defined Benefit Obligation	Changes in the present value of defined benefit obligation 2017 2016 In thousands Balance at January 1, $ 5,235 $ 5,425 Interest costs 151 141 Current service cost 356 359 Benefits paid (641 ) (650 ) Demographic assumptions (28 ) (17 ) Financial assumptions 254 * Past Experience 6 (104 ) Currency Exchange 574 81 Balance at December 31, $ 5,907 $ 5,235 * Represent an amount of less than 1 thousands
Schedule of Changes in Fair Value of Plan Assets	Changes in the fair value of plan assets 2017 2016 In thousands Balance at January 1, $ 4,513 $ 4,638 Expected return 127 121 Contributions by employer 227 311 Benefits paid (586 ) (522 ) Demographic assumptions 1 1 Financial assumptions 1 - Past Experience (11 ) (100 ) Current service cost due to the transfer of real yield from the compensation component to the royalties component in executive insurance policies before 2004 7 (5 ) Currency exchange 484 69 Balance at December 31, $ 4,763 $ 4,513
Schedule of Principal Assumptions Underlying Defined Benefit Plan	The principal assumptions underlying the defined benefit plan 2017 2016 2015 % Discount rate of the plan liability 2.27 3.72 2.6 Future salary increases 4 4 4

CONTINGENT LIABILITIES AND CO45

CONTINGENT LIABILITIES AND COMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of contingent liabilities and commitments [Abstract]
Schedule of Minimum Future Lease Fees for Office and Storage Spaces	Minimum future lease fees for the office and storage spaces as of December 31, 2017 are as follows: In thousands Year 1 $ 590 Year 2 to 5 2,479 Year 6 and thereafter 2,541 $ 5,610
Schedule of Minimum Future Lease Fees for Existing Vehicles	Minimum future lease fees for the existing vehicles as of December 31, 2017 are as follows: In thousands Year 1 $ 443 Year 2 284 Year 3 95 $ 822

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of classes of share capital [abstract]
Schedule of Share Capital	share capital December 31, 2017 December 31, 2016 Authorized Outstanding Authorized Outstanding ordinary shares of NIS 1 par value 70,000,000 40,262,819 70,000,000 36,419,842

SHARE-BASED PAYMENT (Tables)

SHARE-BASED PAYMENT (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Schedule of Expense Recognized in Financial Statements	The share based payment expense that was recognized for services received from employees and directors is presented in the following table: For the Year Ended December 31 2017 2016 2015 In thousands Cost of revenues $ 179 $ 332 $ 564 Research and development 138 134 390 Selling and marketing 48 71 98 General and administrative 118 534 855 Total share-based payment $ 483 $ 1,071 $ 1,907
Schedule of Change of Awards	The following table lists the number of share options, the weighted average exercise prices of share options and modification in employee and service provider option plans during the year: 2017 2016 2015 Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price In NIS In NIS In NIS Outstanding at beginning of year 2,487,236 35.20 2,281,493 38.96 2,396,891 37.98 Granted 458,950 21.10 401,275 15.17 504,075 18.28 Exercised (10,659 ) 18.19 (8,398 ) 18.47 (430,178 ) 11.18 Forfeited (363,155 ) 35.70 (187,134 ) 39.22 (189,295 ) 34.94 Outstanding at end of year 2,572,372 32.47 2,487,236 35.20 2,281,493 38.96 Exercisable at end of year 1,755,253 38.69 1,543,358 40.44 1,182,417 40.39 The weighted average remaining contractual life for the share options 3.22 3.62 4.15
Schedule of Number of RSs and Modification in Employee RSs	The following table lists the number of RSs and modification in employee RSs during the year: Number of RSs 2017 2016 Outstanding at beginning of year 27,333 - Granted 58,835 29,333 End of restriction period (7,656 ) - Forfeited (2,000 ) (2,000 ) Outstanding at end of year 76,512 27,333 The weighted average remaining contractual life for the restricted share 5.92 6.20
Schedule of Inputs to Binomial Model Used for Fair Value Measurement	The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan: 2017 2016 2015 Dividend yield (%) - - - Expected volatility of the share prices (%) 37-45 32-51 42-64 Risk-free interest rate (%) 0.1 – 1.83 0.13 – 1.83 0.07-2.04 Contractual term of up to (years) 6.5 6.5 6.5 Exercise multiple 2 2 2 Weighted average share prices (NIS) 16.05-16.44 15.17 17.17 Expected average forfeiture rate (%) 1-5 0-5 0-5

TAXES ON INCOME (Tables)

TAXES ON INCOME (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of taxes on income [Abstract]
Schedule of Weighted Combination of Applicable Rates	The tax benefits available under Approved Enterprise or Privileged Enterprise relate only to taxable income attributable to the specific Approved Enterprise or Privileged Enterprise, and the Company's effective tax rate will be the result of a weighted combination of the applicable rates. Tax Exemption Period Reduced Tax Period Rate of Reduced Tax Percent of Foreign Ownership 2 years 5 years 25% 0-25% 2 years 8 years 25% 25-49% 2 years 8 years 20% 49-74% 2 years 8 years 15% 74-90% 2 years 8 years 10% 90-100%
Schedule of Current Taxes on Income	Current taxes on income Year ended December 31, 2017 2016 2015 In thousands Current taxes $ 129 $ 362 $ - Taxes in respect of prior years 140 1,360 - $ 269 $ 1,722 $ -

SUPPLEMENTARY INFORMATION TO 49

SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF PROFIT AND LOSS (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of supplementary information to the statements of comprehensive loss [Abstract]
Schedule of Additional Information about Revenues	Year Ended December 31, 2017 2016 2015 In thousands a. Additional information about revenues Revenues from major customers each of whom amount to 10% or more, of total revenues Customer A – Proprietary products Segment $ 60,383 $ 40,451 $ 26,032 Customer B – Proprietary products Segment and Distribution Segment - 10,225 10,306 $ 60,383 $ 50,676 $ 36,338
Schedule of Revenues Based on Location of Customers	Revenues based on the location of the customers, are as follows: Year Ended December 31, 2017 2016 2015 In thousands U.S.A. $ 60,405 $ 40,585 $ 26,559 Israel 26,355 25,340 30,624 Europe 5,348 3,825 3,223 Latin America 5,248 4,221 6,036 Asia 4,979 3,028 2,900 Others 490 495 564 $ 102,825 $ 77,494 $ 69,906
Schedule of Income and Expenses	Year Ended December 31, 2017 2016 2015 In thousands b. Cost of goods sold Cost of materials $ 41,179 $ 36,154 $ 38,848 Salary and related expenses 13,137 10,596 9,991 Depreciation and amortization 2,504 2,443 2,383 Energy 1,202 959 922 Subcontractors 3,995 2,833 2,112 Other manufacturing expenses 1,572 1,057 1,220 63,589 54,042 55,476 Decrease (increase) in inventories 7,148 2,092 (935 ) $ 70,737 $ 56,134 $ 54,541 c. Research and development Salary and related expenses $ 6,413 $ 5,237 $ 4,566 Subcontractors 3,392 8,318 8,002 Materials and allocation of facility costs 1,101 1,907 3,386 Others 1,067 783 576 $ 11,973 $ 16,245 $ 16,530 d. Selling and marketing Salary and related expenses $ 1,470 $ 1,272 $ 1,227 Marketing support 95 79 368 Packing, shipping and delivery 607 494 454 Marketing and advertising 627 337 560 Registration and marketing fees 1,162 796 794 Others 437 265 249 $ 4,398 $ 3,243 $ 3,652 Year Ended December 31, 2017 2016 2015 In thousands e. General and administrative Salary and related expenses $ 3,138 $ 3,029 $ 2,604 Employees welfare 2,182 1,465 1,391 Professional fees 1,497 1,378 1,482 Depreciation, amortization and impairment 649 712 524 Others 807 769 606 $ 8,273 $ 7,353 $ 6,607 f. Financial incomes and expenses Financial incomes Interest income $ 500 $ 469 $ 463 Financial expenses Interest and amortization from debentures $ - $ - $ 731 Fees and interest paid to financial institutions 162 126 111 Others - - 92 $ 162 $ 126 $ 934

INCOME (LOSS) PER SHARE (Tables

INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2017
Income (loss) per share attributable to equity holders of the Company:
Schedule of Details of Number of Shares and Income (Loss)	Details of the number of shares and income (loss) used in the computation of income (loss) per share Year Ended December 31 2017 2016 2015 Weighted Number of Shares Income Attributed to equity holders of the Company Weighted Number of Shares Loss Attributed to equity holders of the Company Weighted Number of Shares Loss Attributed to equity holders of the Company In thousands For the computation of basic income (loss) 37,970,697 $ 6,901 36,418,833 $ (6,733 ) 36,245,813 $ (11,270 ) Effect of potential dilutive ordinary shares 74,400 - - - - - For the computation of diluted income (loss) 38,045,097 $ 6,901 36,418,833 $ (6,733 ) 36,245,813 $ (11,270 )

OPERATING SEGMENTS (Tables)

OPERATING SEGMENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of operating segments [abstract]
Schedule of Reporting on Operating Segments	Reporting on operating segments Proprietary Products Distribution Total In thousands Year Ended December 31, 2017 Revenues $ 79,559 $ 23,266 $ 102,825 Gross profit $ 28,224 $ 3,864 $ 32,088 Unallocated corporate expenses (24,644 ) Finance expense, net (274 ) Income before taxes on income $ 7,170 Proprietary Products Distribution Total In thousands Year Ended December 31, 2016 Revenues $ 55,958 $ 21,536 $ 77,494 Gross profit $ 18,235 $ 3,125 $ 21,360 Unallocated corporate expenses (26,841 ) Finance income, net 470 Loss before taxes on income $ (5,011 ) Proprietary Products Distribution Total In thousands Year Ended December 31, 2015 Revenues $ 42,952 $ 26,954 $ 69,906 Gross profit $ 12,051 $ 3,314 $ 15,365 Unallocated corporate expenses (26,789 ) Finance income, net 154 Loss before taxes on income $ (11,270 )

BALANCES AND TRANSACTIONS WIT52

BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of transactions between related parties [abstract]
Schedule of Balances with Related Parties	Balances with related parties December 31, 2017 December 31, 2016 In thousands December 31, 2017 Other accounts payables $ 292 $ 230 Employee benefit liabilities, net $ 92 $ 170 Trade receivable $ 2,382 $ 675
Schedule of Benefits to Related Parties	Benefits to related parties Year Ended December 31, 2017 2016 In thousands Salary and related expenses to those employed by the Company or on its behalf $ 460 $ 473 Salary of directors not employed by the Company or on its behalf $ 107 $ 122 Number of People to whom the Salary and Benefits Refer Related and related parties employed by the Company or on its behalf 2 2 Directors not employed by the Company 2 3 4 5
Schedule of Benefits to Key Executive Personnel	Benefits to key executive personnel (including non-related parties) Year Ended December 31, 2017 2016 2015 In thousands Short-term benefits $ 2,719 $ 2,453 $ 2,144 Share-based payment 310 460 650 Other long-term benefits 6 28 61 $ 3,035 $ 2,941 $ 2,855
Schedule of Transactions with Related Parties	Transactions with related parties Year Ended December 31, 2017 2016 2015 In thousands Sales $ 3,455 $ 2,230 $ 2,795 Selling and marketing expenses $ 121 $ 101 $ 114 General and administrative expenses $ 446 $ 503 $ 526

SIGNIFICANT ACCOUNTING POLICI53

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of significant accounting policies [Abstract]
Allowance for doubtful accounts		$ 399

SIGNIFICANT ACCOUNTING POLICI54

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Lives for Property, Plant and Equipment) (Details)	12 Months Ended
	Dec. 31, 2017
Building [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation percentage on straight-line basis over the useful life of the assets (in %)	2.5-4
Mainly %	4
Machinery and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation percentage on straight-line basis over the useful life of the assets (in %)	10-20
Mainly %	15
Vehicles [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation percentage on straight-line basis over the useful life of the assets (in %)	15
Mainly %	15
Computers, software, equipment and office furniture [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation percentage on straight-line basis over the useful life of the assets (in %)	6-33
Mainly %	33
Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation percentage on straight-line basis over the useful life of the assets (in %)	-	[1]
Mainly %	10
[1]	Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement.

DISCLUSURE OF NEW IFRS IN THE P

DISCLUSURE OF NEW IFRS IN THE PERIOD (Details) $ in Thousands	Dec. 31, 2017USD ($)
Disclusure Of New Ifrs In Period Details
Increase of deferred revenue	$ 757

CASH AND CASH EQUIVALENTS (Narr

CASH AND CASH EQUIVALENTS (Narrative) (Details) - Fixed interest rate [Member]	Dec. 31, 2017	Dec. 31, 2016
Disclosure of financial assets [line items]
Interest rate on deposits	1.53%	1.12%
NIS [Member]
Disclosure of financial assets [line items]
Interest rate on deposits	0.01%	0.01%

CASH AND CASH EQUIVALENTS (Sche

CASH AND CASH EQUIVALENTS (Schedule of Cash and Cash Equivalents) (Details) - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash and cash equivalents [abstract]
Cash and deposits for immediate withdrawal		$ 8,539	$ 7,891
Cash equivalents in USD deposits	[1]	4,001	2,001
Cash equivalents in NIS deposits	[2]	141	76
Cash and cash equivalents		$ 12,681	$ 9,968	$ 5,047	$ 14,546
[1]	The deposits bear interest of 1.53% and 1.12% per year, as of December 31, 2017 and 2016, respectively.
[2]	The deposits bear interest of 0.01% per year, as of each December 31, 2017 and 2016.

SHORT-TERM INVESTMENTS (Narrati

SHORT-TERM INVESTMENTS (Narrative) (Details) - Fixed interest rate [Member]	Dec. 31, 2017	Dec. 31, 2016
Disclosure of financial assets [line items]
Interest rate on deposits	1.53%	1.12%
Bottom of range [Member]
Disclosure of financial assets [line items]
Interest rate on deposits	1.70%	1.69%
Top of range [Member]
Disclosure of financial assets [line items]
Interest rate on deposits	2.30%	1.84%

SHORT-TERM INVESTMENTS (Schedul

SHORT-TERM INVESTMENTS (Schedule of Short-term Investments) (Details) - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016
Disclosure of short-term investments [Abstract]
Marketable securities (equity and debt) at fair value through profit or loss		$ 1,663	$ 1,490
Bank deposits in USD	[1]	20,078	8,010
Available for sale debt securities		8,597	9,164
Short-term investments		$ 30,338	$ 18,664
[1]	The deposits bear interest of 1.70%-2.3% and 1.69%- 1.84% per year, as of December 31, 2017 and 2016, respectively.

TRADE RECEIVABLES, NET (Schedul

TRADE RECEIVABLES, NET (Schedule of Trade Receivables, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Open accounts:
In NIS	$ 8,263	$ 9,326
In USD	22,284	10,816
Total open accounts	30,547	20,142
Checks receivable	115	45
Trade receivables, gross	30,662	20,187
Less allowance for doubtful accounts		(399)
Trade receivables, net	$ 30,662	$ 19,788

TRADE RECEIVABLES, NET (Sched61

TRADE RECEIVABLES, NET (Schedule of Allowance for Doubtful Accounts) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Trade and other current receivables [abstract]
December 31, 2016	$ (399)
Bad debt recognition	399
December 31, 2017

TRADE RECEIVABLES, NET (Sched62

TRADE RECEIVABLES, NET (Schedule of Analysis of Past Due but Not Impaired Trade Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of provision matrix [line items]
Trade receivables	$ 30,547	$ 19,743
Neither past due nor impaired [Member]
Disclosure of provision matrix [line items]
Trade receivables	29,692	17,769
Past due trade receivables with aging of Up to 30 Days [Member]
Disclosure of provision matrix [line items]
Trade receivables	680	1,891
Past due trade receivables with aging of 30-60 Days [Member]
Disclosure of provision matrix [line items]
Trade receivables	21	24
Past due trade receivables with aging of 60-90 Days [Member]
Disclosure of provision matrix [line items]
Trade receivables	152	43
Past due trade receivables with aging of 90-120 Days [Member]
Disclosure of provision matrix [line items]
Trade receivables	2	6
Past due trade receivables with aging of Over 120 days [Member]
Disclosure of provision matrix [line items]
Trade receivables		$ 10

OTHER ACCOUNTS RECEIVABLES (Sch

OTHER ACCOUNTS RECEIVABLES (Schedule of Other Accounts Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of other accounts receivables [Abstract]
Materials for clinical trials and inventory designated for R&D activities	$ 635	$ 1,229
Prepaid expenses	822	1,057
Government authorities	563	374
Accrued interest	66	82
Other	46	321
Other accounts receivables	$ 2,132	$ 3,063

INVENTORIES (Narrative) (Detail

INVENTORIES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Classes of current inventories [abstract]
Cost of inventories recognised as expense during period	$ 460	$ 544	$ 470

INVENTORIES (Schedule of Invent

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Classes of current inventories [abstract]
Finished products	$ 5,168	$ 6,542
Purchased products	2,695	5,607
Work in progress	6,159	6,227
Raw materials	7,048	7,218
Inventories	$ 21,070	$ 25,594

PROPERTY, PLANT AND EQUIPMENT66

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)m²	Dec. 31, 2016USD ($)
Disclosure of detailed information about property, plant and equipment [line items]
Area of capitalized leasing rights from Israel Land Administration | m²	16,880
Lease period with Israel Land Administration	2,058
Extension option for lease with with Israel Land Administration (in years)	49 years
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Cost of facilities, machinery and equipment	$ 431	$ 510
Cost [Member] | Machinery and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Borrowing costs of machinery and equipment	$ 44	$ 11

PROPERTY, PLANT AND EQUIPMENT67

PROPERTY, PLANT AND EQUIPMENT (Schedule of Composition and Movement of Property, Plant and Equipment) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about property, plant and equipment [line items]
Balance		$ 22,579
Balance		25,178	$ 22,579
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		60,769	57,141
Additions		6,130	4,752
Sale and write-off		(1,037)	(1,124)
Balance		65,862	60,769
Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		38,190	35,778
Depreciation and impairment		3,523	3,368
Sale and write-off		(1,029)	(956)
Balance		40,684	38,190
Depreciated cost as of December 31, 2017		25,178	22,579
Land and Buildings [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	[1]	27,618	26,701
Additions	[1]	781	963
Sale and write-off	[1]		(46)
Balance	[1]	28,399	27,618
Land and Buildings [Member] | Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	[1]	12,606	11,237
Depreciation and impairment	[1]	1,310	1,402
Sale and write-off	[1]		(33)
Balance	[1]	13,916	12,606
Depreciated cost as of December 31, 2017	[1]	14,483	15,012
Machinery and equipment [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	[1],[2]	26,485	24,111
Additions	[1],[2]	3,151	3,220
Sale and write-off	[1],[2]	(34)	(846)
Balance	[1],[2]	29,602	26,485
Machinery and equipment [Member] | Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance	[1],[2]	19,972	19,310
Depreciation and impairment	[1],[2]	1,492	1,355
Sale and write-off	[1],[2]	(34)	(693)
Balance	[1],[2]	21,430	19,972
Depreciated cost as of December 31, 2017	[1],[2]	8,172	6,513
Vehicles [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		94	94
Additions
Sale and write-off		(28)
Balance		66	94
Vehicles [Member] | Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		86	83
Depreciation and impairment		1	3
Sale and write-off		(28)
Balance		59	86
Depreciated cost as of December 31, 2017		7	8
Computers, software, equipment and office furniture [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		5,520	5,156
Additions		1,002	507
Sale and write-off			(143)
Balance		6,522	5,520
Computers, software, equipment and office furniture [Member] | Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		4,559	4,136
Depreciation and impairment		635	564
Sale and write-off			(141)
Balance		5,194	4,559
Depreciated cost as of December 31, 2017		1,328	961
Leasehold improvements [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		1,052	1,079
Additions		1,196	62
Sale and write-off		(975)	(89)
Balance		1,273	1,052
Leasehold improvements [Member] | Accumulated Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		967	1,012
Depreciation and impairment		85	44
Sale and write-off		(967)	(89)
Balance		85	967
Depreciated cost as of December 31, 2017		$ 1,188	$ 85
[1]	Including labor costs charged in 2017 and 2016 to the cost of facilities, machinery and equipment in the amount of $431 thousands and $510 thousands, respectively.
[2]	Including financing costs of $44 thousands and $11 thousands capitalized in 2017 and 2016 respectively, to the cost of machinery and equipment.

PROPERTY, PLANT AND EQUIPMENT68

PROPERTY, PLANT AND EQUIPMENT (Schedule of Capitalized Leasing Rights of Land from Israel Land Administration) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about property, plant and equipment [abstract]
Under finance lease	$ 1,016	$ 1,029

OTHER LONG TERM ASSETS (Schedul

OTHER LONG TERM ASSETS (Schedule of Other Long Term Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Miscellaneous non-current assets [abstract]
Long term pre-paid expenses	$ 49	$ 40

TRADE PAYABLES (Schedule of Tra

TRADE PAYABLES (Schedule of Trade Payables) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Trade and other current payables [abstract]
Open debts mainly in USD	$ 11,246	$ 11,187
Open debts in NIS	6,789	5,038
Open debts, total	18,035	16,225
Notes payable	1	52
Trade payables	$ 18,036	$ 16,277

OTHER ACCOUNTS PAYABLES (Schedu

OTHER ACCOUNTS PAYABLES (Schedule of Other Accounts Payables) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of other accounts payable [Abstract]
Employees and payroll accruals	$ 4,735	$ 4,135
Derivatives financial instruments	8	32
Accrued Expenses and Others	1,077	1,447
Other accounts payables	$ 5,820	$ 5,614

LOANS AND CAPITAL LEASES (Narra

LOANS AND CAPITAL LEASES (Narrative) (Details) ₪ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2017ILS (₪)	Dec. 31, 2016USD ($)	Dec. 31, 2016ILS (₪)	Dec. 31, 2015USD ($)
Disclosure of detailed information about borrowings [line items]
Capital lease balance	$ 274		$ 103
Proceeds from long-term loans	$ 279		$ 1,701		$ 197
Bottom of range [Member]
Disclosure of detailed information about borrowings [line items]
Interest rate	3.15%
Top of range [Member]
Disclosure of detailed information about borrowings [line items]
Interest rate	3.55%
NIS [Member]
Disclosure of detailed information about borrowings [line items]
Proceeds from long-term loans | ₪		₪ 1,000		₪ 6,585

LOANS AND CAPITAL LEASES (Sched

LOANS AND CAPITAL LEASES (Schedule of Loans and Capital Leases) (Details) - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016
Disclosure of loans and capital leases [abstract]
Total loans and capital leases	[1]	$ 1,984	$ 1,776
Less current maturities		614	412
Long term loans and capital leases		$ 1,370	$ 1,364
[1]	The capital lease balance was $274 thousands and $103 thousands, as of December 31, 2017 and 2016, respectively.

FINANCIAL INSTRUMENTS (Narrativ

FINANCIAL INSTRUMENTS (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of detailed information about hedges [line items]
Net unrecognized loss recorded in other comprehensive loss	$ 329	$ 47	$ 71
Cash flow hedges [Member]
Disclosure of detailed information about hedges [line items]
Fair value of derivative instrument designated as hedging instrument	52
Open transactions for derivative instruments designated as hedging	770
Net unrecognized loss recorded in other comprehensive loss	71
Derivatives instruments not designated as hedging [Member]
Disclosure of detailed information about hedges [line items]
Fair value of the derivative instruments	60
Open transactions for derivative instruments not designated as hedging	$ 5,800

FINANCIAL INSTRUMENTS (Schedule

FINANCIAL INSTRUMENTS (Schedule of Classification of Financial Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about financial instruments [line items]
Financial assets	$ 43,019	$ 28,632
Financial liabilities	1,992	1,808
Financial liabilities at fair value through profit or loss: Derivatives instruments [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	8	32
Financial liabilities measured at amortized cost: Bank loans and capital leases [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities	1,984	1,776
Financial assets at fair value: Marketable securities (equity and debt) [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	1,663	1,490
Financial assets at fair value through- Available for sale debt securities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	8,597	9,164
Derivatives instruments [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	8,539	7,891
Financial assets at cost - Short term bank deposits [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets	$ 24,220	$ 10,087

FINANCIAL INSTRUMENTS (Schedu76

FINANCIAL INSTRUMENTS (Schedule of Financial Liabilities based on Contractual Undiscounted Payments) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of maturity analysis for derivative financial liabilities [line items]
Trade payables	$ 18,036	$ 16,277
Other accounts payables	5,820	5,614
Long term loans and capital leases (including interest)	2,095	1,903
Financial liabilities	25,951	23,794
Less than one year [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
Trade payables	18,036	16,277
Other accounts payables	5,820	5,614
Long term loans and capital leases (including interest)	669	464
Financial liabilities	24,525	22,355
1 to 2 [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
Trade payables
Other accounts payables
Long term loans and capital leases (including interest)	634	461
Financial liabilities	634	461
2 to 3 [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
Trade payables
Other accounts payables
Long term loans and capital leases (including interest)	532	429
Financial liabilities	532	429
3 to 5 [Member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
Trade payables
Other accounts payables
Long term loans and capital leases (including interest)	260	549
Financial liabilities	$ 260	$ 549

FINANCIAL INSTRUMENTS (Schedu77

FINANCIAL INSTRUMENTS (Schedule of Changes in Liabilities Arising From Financing Activities) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Beginning	$ 1,776
Payments	(530)
Foreign exchange movement	177
Cash from new loans	279
New leases	282
Ending	1,984
Bank loans [Member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Beginning	1,673
Payments	(419)
Foreign exchange movement	177
Cash from new loans	279
New leases
Ending	1,710
Capital lease [Member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Beginning	103
Payments	(111)
Foreign exchange movement
Cash from new loans
New leases	282
Ending	$ 274

FINANCIAL INSTRUMENTS (Schedu78

FINANCIAL INSTRUMENTS (Schedule of Carrying Amount and Fair Value of Financial Instruments) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of financial liabilities [line items]
Financial liabilities Carrying Amount	$ 1,992	$ 1,808
Bank loans and capital leases [Member]
Disclosure of financial liabilities [line items]
Financial liabilities Carrying Amount	1,984	1,776
Financial liabilities Fair Value	$ 1,984	$ 1,761

FINANCIAL INSTRUMENTS (Schedu79

FINANCIAL INSTRUMENTS (Schedule of Classification of Financial Instruments by Fair Value Hierarchy) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Level 1 [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value	$ 1,663	$ 1,490
Level 1 [Member] | Marketable securities at fair value through profit or loss [Member] | Equity shares [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value	77	70
Level 1 [Member] | Marketable securities at fair value through profit or loss [Member] | Mutual funds [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value	456	388
Level 1 [Member] | Marketable securities at fair value through profit or loss [Member] | Debt securities (corporate and government) [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value	1,130	1,032
Level 1 [Member] | Financial assets at fair value through- Available for sale debt securities [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value
Level 1 [Member] | Derivatives instruments [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value
Level 2 [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value	8,589	9,132
Level 2 [Member] | Marketable securities at fair value through profit or loss [Member] | Equity shares [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value
Level 2 [Member] | Marketable securities at fair value through profit or loss [Member] | Mutual funds [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value
Level 2 [Member] | Marketable securities at fair value through profit or loss [Member] | Debt securities (corporate and government) [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value
Level 2 [Member] | Financial assets at fair value through- Available for sale debt securities [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value	8,597	9,164
Level 2 [Member] | Derivatives instruments [Member]
Disclosure of financial assets [line items]
Financial assets measured at fair value	$ (8)	$ (32)

FINANCIAL INSTRUMENTS (Schedu80

FINANCIAL INSTRUMENTS (Schedule of Sensitivity Test) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
5% increase in market price [Member]
Sensitivity test to changes in market price of listed Securities
Gain (loss) from sensitivity test to changes in market price of listed Securities	$ 513	$ 535
5% decrease in market price [Member]
Sensitivity test to changes in market price of listed Securities
Gain (loss) from sensitivity test to changes in market price of listed Securities	(513)	(535)
5% increase in NIS [Member]
Sensitivity test to changes in foreign currency:
Gain (loss) from sensitivity test to changes in foreign currency	(143)	19
5% decrease in NIS [Member]
Sensitivity test to changes in foreign currency:
Gain (loss) from sensitivity test to changes in foreign currency	143	(19)
5% increase in Euro [Member]
Sensitivity test to changes in foreign currency:
Gain (loss) from sensitivity test to changes in foreign currency	(135)	(184)
5% decrease in Euro [Member]
Sensitivity test to changes in foreign currency:
Gain (loss) from sensitivity test to changes in foreign currency	$ 135	$ 184

FINANCIAL INSTRUMENTS (Schedu81

FINANCIAL INSTRUMENTS (Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Bank loans and capital leases measured at amortized cost | NIS [Member]
In NIS:
Linkage terms of financial liabilities by groups of financial instruments pursuant to IAS 39	$ 1,984	$ 1,776

EMPLOYEE BENEFIT LIABILITIES,82

EMPLOYEE BENEFIT LIABILITIES, NET (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Expenses for defined benefit deposit	$ 884	$ 669	$ 702
Discount rates [Member]
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Reasonably possible increase in actuarial assumption	1.00%
Reasonably possible decrease in actuarial assumption	1.00%
Increase (decrease) in defined benefit obligation from a 1% increase in actuarial assumption	$ 380
Increase (decrease) in defined benefit obligation from a 1% decrease in actuarial assumption	$ (309)
Expected salary growth [Member]
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Reasonably possible increase in actuarial assumption	1.00%
Increase (decrease) in defined benefit obligation from a 1% increase in actuarial assumption	$ 362
Increase (decrease) in defined benefit obligation from a 1% decrease in actuarial assumption	$ (298)

EMPLOYEE BENEFIT LIABILITIES,83

EMPLOYEE BENEFIT LIABILITIES, NET (Schedule of Expenses Recognized in Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of defined benefit plans [abstract]
Current service cost	$ 356	$ 359	$ 391
Interest expenses, net	23	20	18
Current service cost (income) due to the transfer of real yield from the compensation component to the royalties' component in executive insurance policies before 2004.	(7)	5	(10)
Total employee benefit expenses	372	384	399
Actual (negative) return on plan assets	$ 119	$ 22	$ (12)

EMPLOYEE BENEFIT LIABILITIES,84

EMPLOYEE BENEFIT LIABILITIES, NET (Schedule of Expenses are Presented in Statement of Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of defined benefit plans [line items]
Total employee benefit expenses	$ 372	$ 384	$ 399
Cost of revenues [Member]
Disclosure of defined benefit plans [line items]
Total employee benefit expenses	211	228	209
Research and development [Member]
Disclosure of defined benefit plans [line items]
Total employee benefit expenses	57	62	90
Selling and marketing [Member]
Disclosure of defined benefit plans [line items]
Total employee benefit expenses	16	13	18
General and administrative [Member]
Disclosure of defined benefit plans [line items]
Total employee benefit expenses	$ 88	$ 81	$ 82

EMPLOYEE BENEFIT LIABILITIES,85

EMPLOYEE BENEFIT LIABILITIES, NET (Schedule of Plan Assets (Liabilities), Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of defined benefit plans [abstract]
Defined benefit obligation	$ 5,907	$ 5,235
Fair value of plan assets	4,763	4,513
Total liabilities, net	$ 1,144	$ 722

EMPLOYEE BENEFIT LIABILITIES,86

EMPLOYEE BENEFIT LIABILITIES, NET (Schedule of Changes in Present Value of Defined Benefit Obligation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016		Dec. 31, 2015
Disclosure of net defined benefit liability (asset) [line items]
Interest costs	$ (23)	$ (20)		$ (18)
Current service cost	(356)	(359)		(391)
Defined Benefit Obligation [Member]
Disclosure of net defined benefit liability (asset) [line items]
Balance at January 1,	5,235	5,425
Interest costs	151	141
Current service cost	356	359
Benefits paid	(641)	(650)
Demographic assumptions	(28)	(17)
Financial assumptions	254		[1]
Past Experience	6	(104)
Currency Exchange	574	81
Balance at December 31,	$ 5,907	$ 5,235		$ 5,425
[1]	Represent an amount of less than 1 thousands

EMPLOYEE BENEFIT LIABILITIES,87

EMPLOYEE BENEFIT LIABILITIES, NET (Schedule of Changes in Fair Value of Plan Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of net defined benefit liability (asset) [line items]
Balance at January 1,	$ 4,513
Expected return	119	$ 22	$ (12)
Current service cost due to the transfer of real yield from the compensation component to the royalties component in executive insurance policies before 2004.	(7)	5	(10)
Balance at December 31,	4,763	4,513
Plan assets [Member]
Disclosure of net defined benefit liability (asset) [line items]
Balance at January 1,	4,513	4,638
Expected return	127	121
Contributions by employer	227	311
Benefits paid	(586)	(522)
Demographic assumptions	1	1
Financial assumptions	1
Past Experience	(11)	(100)
Current service cost due to the transfer of real yield from the compensation component to the royalties component in executive insurance policies before 2004.	7	(5)
Currency exchange	484	69
Balance at December 31,	$ 4,763	$ 4,513	$ 4,638

EMPLOYEE BENEFIT LIABILITIES,88

EMPLOYEE BENEFIT LIABILITIES, NET (Schedule of Principal Assumptions Underlying Defined Benefit Plan) (Details)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of defined benefit plans [abstract]
Discount rate of the plan liability	2.27%	3.72%	2.60%
Future salary increases	4.00%	4.00%	4.00%

CONTINGENT LIABILITIES AND CO89

CONTINGENT LIABILITIES AND COMMITMENTS (Narrative) (Details) - USD ($) $ in Millions	Aug. 02, 2012	Aug. 23, 2010	Dec. 31, 2017
Baxter Healthcare Corporation [Member]
Disclosure of contingent liabilities [line items]
Agreement term		30 years
Agreement payment amount		$ 45
Minimum amount purchased by third party from Kamada through five years from signing the agreement		60
Minimum yearly royalties to be paid by shire starting from the beginning of the sale of Glassia produced by Shire in accordance with the License Agreement		$ 5
Amount received from Distribution Agreement			$ 39.5
Maximum cost of experiment with Glassia			10
Revenue received			4.2
Distribution Agreement [Member]
Disclosure of contingent liabilities [line items]
Amount received from Distribution Agreement			9
Total expected proceeds from agreement	$ 60
Revenue received			$ 9
Operating lease agreements [Member]
Disclosure of contingent liabilities [line items]
Agreements expiration date			2,026
Vehicles [Member]
Disclosure of contingent liabilities [line items]
Agreements expiration date			2018-2020
Patents [Member]
Disclosure of contingent liabilities [line items]
Agreements expiration date			15 years

CONTINGENT LIABILITIES AND CO90

CONTINGENT LIABILITIES AND COMMITMENTS (Schedule of Minimum Future Lease Fees for Office and Storage Spaces) (Details) - Building [Member] $ in Thousands	Dec. 31, 2017USD ($)
Disclosure of finance lease and operating lease by lessee [line items]
Minimum future lease fees for the office and storage spaces	$ 5,610
Year 1 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum future lease fees for the office and storage spaces	590
Year 2 to 5 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum future lease fees for the office and storage spaces	2,479
Year 6 and thereafter [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum future lease fees for the office and storage spaces	$ 2,541

CONTINGENT LIABILITIES AND CO91

CONTINGENT LIABILITIES AND COMMITMENTS (Schedule of Minimum Future Lease Fees for Existing Vehicles) (Details) - Vehicles [Member] $ in Thousands	Dec. 31, 2017USD ($)
Disclosure of finance lease and operating lease by lessee [line items]
Minimum future lease fees for the existing vehicles	$ 822
Year 1 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum future lease fees for the existing vehicles	443
Year 2 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum future lease fees for the existing vehicles	284
Year 3 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum future lease fees for the existing vehicles	$ 95

GUARANTEES AND CHARGES (Details

GUARANTEES AND CHARGES (Details) - Dec. 31, 2017 ₪ in Thousands, $ in Thousands	USD ($)	ILS (₪)
Disclosure of contingent liabilities [line items]
Value of loans for which collateral has been pledged | ₪		₪ 8,355
Contingent liability for guarantees [member]
Disclosure of contingent liabilities [line items]
Contingent liability | $	$ 246

EQUITY (Narrative) (Details)

EQUITY (Narrative) (Details) $ / shares in Units, $ in Thousands	Aug. 02, 2017$ / sharesshares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2017₪ / shares	Dec. 31, 2016₪ / shares
Disclosure of classes of share capital [abstract]
Share options, exercised		10,659	8,398	430,178
Ordinary shares issued from share options exercised		1,988	1,101
Ordinary shares par value | ₪ / shares					₪ 1	₪ 1
Proceeds from share options exercised | $		$ 3
Shares issued	3,333,334
Sahre price | $ / shares	$ 4.50
Additional shares issued	500,000
Proceeds from issuance of ordinary shares, net | $		$ 15,568

EQUITY (Schedule of Share Capit

EQUITY (Schedule of Share Capital) (Details) - ₪ / shares	Dec. 31, 2017	Dec. 31, 2016
Disclosure of classes of share capital [abstract]
Ordinary shares of NIS 1 par value, Authorized	70,000,000	70,000,000
Ordinary shares of NIS 1 par value, Outstanding	40,262,819	36,419,842
Ordinary shares par value	₪ 1	₪ 1

SHARE-BASED PAYMENT (Narrative)

SHARE-BASED PAYMENT (Narrative) (Details)	1 Months Ended					12 Months Ended
	Nov. 30, 2017USD ($)shares	Sep. 30, 2016	Aug. 30, 2016USD ($)shares	Jun. 30, 2015USD ($)shares	Apr. 27, 2015USD ($)shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2017ILS (₪)shares	Nov. 30, 2017ILS (₪)	Dec. 31, 2016ILS (₪)shares	Aug. 30, 2016ILS (₪)	Dec. 31, 2015ILS (₪)shares	Jun. 30, 2015ILS (₪)shares	Apr. 27, 2015ILS (₪)shares	Dec. 31, 2014ILS (₪)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option granted						458,950	401,275	504,075
Exercisable shares						1,755,253	1,543,358	1,182,417	1,755,253		1,543,358		1,182,417
Exercise price of options | ₪									₪ 32.47		₪ 35.2		₪ 38.96			₪ 37.98
Dividend yield
Bottom of range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of options | ₪									15		15
Expected volatility						37.00%	32.00%	42.00%
Risk-free interest rate						0.10%	0.13%	0.07%
Expected average forfeiture rate						1.00%	0.00%	0.00%
Top of range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of options | ₪									₪ 57		₪ 57
Expected volatility						45.00%	51.00%	64.00%
Risk-free interest rate						1.83%	1.83%	2.04%
Expected average forfeiture rate						5.00%	5.00%	5.00%
Number of RSs [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option granted						58,835	29,333
2011 Option Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting description of options		Restricted shares ("RS") awards (options and RS) that generally vest during a four-year period following the date of the grant in 13 installments: 25% of the options vest on the first anniversary of the grant date and 6.25% options vest at the end of each quarter thereafter.
Chief Executive Officer [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option granted	18,000		18,000		120,000
Exercisable shares					120,000										120,000
Exercise price of options | ₪										₪ 21.99		₪ 15.2			₪ 18.74
Fair value of options | $	$ 26,000		$ 41,000		$ 176,000
Chief Executive Officer [Member] | Number of RSs [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option granted	6,000		6,000
Fair value of options | $	$ 28,000		$ 30,000
Employees options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option granted						405,950	320,775	356,075
Fair value of options | $						$ 597,000	$ 548,000	$ 749,000
Employees options [Member] | Number of RSs [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting description of options						RSs are exercisable in 13 installments, 25% of the RSs vest on the first anniversary of the grant date and 6.25% vest at the end of each quarter thereafter into ordinary shares.
Option granted						52,835
Fair value of options | $						$ 238,000
Directors options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option granted	35,000		50,000	25,000
Exercisable shares				25,000										25,000
Exercise price of options | ₪										₪ 21.99		₪ 15.2		₪ 18.74
Fair value of options | $	$ 51,000		$ 114,000	$ 37,000
Consultants options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option granted					3,000
Exercisable shares					3,000										3,000
Exercise price of options | ₪															₪ 18.74
Fair value of options | $					$ 4,000

SHARE-BASED PAYMENT (Schedule o

SHARE-BASED PAYMENT (Schedule of Expense Recognized in Financial Statements) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total share-based payment	$ 483	$ 1,071	$ 1,907
Cost of revenues [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total share-based payment	179	332	564
Research and development [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total share-based payment	138	134	390
Selling and marketing [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total share-based payment	48	71	98
General and administrative [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total share-based payment	$ 118	$ 534	$ 855

SHARE-BASED PAYMENT (Schedule97

SHARE-BASED PAYMENT (Schedule of Change of Awards) (Details)	12 Months Ended
	Dec. 31, 2017ILS (₪)sharesyr	Dec. 31, 2016ILS (₪)sharesyr	Dec. 31, 2015ILS (₪)sharesyr
Number of Options
Outstanding at beginning of year | shares	2,487,236	2,281,493	2,396,891
Granted | shares	458,950	401,275	504,075
Exercised | shares	(10,659)	(8,398)	(430,178)
Forfeited | shares	(363,155)	(187,134)	(189,295)
Outstanding at end of year | shares	2,572,372	2,487,236	2,281,493
Exercisable at end of year | shares	1,755,253	1,543,358	1,182,417
Weighted Average Exercise Price
Outstanding at beginning of year | ₪	₪ 35.2	₪ 38.96	₪ 37.98
Granted | ₪	21.1	15.17	18.28
Exercised | ₪	18.19	18.47	11.18
Forfeited | ₪	35.7	39.22	34.94
Outstanding at end of year | ₪	32.47	35.2	38.96
Exercisable at end of year | ₪	₪ 38.69	₪ 40.44	₪ 40.39
The weighted average remaining contractual life for the share options | yr	3.22	3.62	4.15

SHARE-BASED PAYMENT (Schedule98

SHARE-BASED PAYMENT (Schedule of Number of RSs and Modification in Employee RSs) (Details)	12 Months Ended
	Dec. 31, 2017sharesyr	Dec. 31, 2016sharesyr	Dec. 31, 2015sharesyr
Disclosure of classes of share capital [line items]
Outstanding at beginning of year	2,487,236	2,281,493	2,396,891
Granted	458,950	401,275	504,075
Forfeited	(363,155)	(187,134)	(189,295)
Outstanding at end of year	2,572,372	2,487,236	2,281,493
The weighted average remaining contractual life for the restricted share | yr	3.22	3.62	4.15
Number of RSs [Member]
Disclosure of classes of share capital [line items]
Outstanding at beginning of year	27,333
Granted	58,835	29,333
End of restriction period	(7,656)
Forfeited	(2,000)	(2,000)
Outstanding at end of year	76,512	27,333
The weighted average remaining contractual life for the restricted share | yr	5.92	6.20

SHARE-BASED PAYMENT (Schedule99

SHARE-BASED PAYMENT (Schedule of Inputs to Binomial Model Used for Fair Value Measurement) (Details)	12 Months Ended
	Dec. 31, 2017USD ($)yr	Dec. 31, 2017ILS (₪)yr	Dec. 31, 2016USD ($)yr	Dec. 31, 2016ILS (₪)yr	Dec. 31, 2015USD ($)yr	Dec. 31, 2015ILS (₪)yr
Disclosure of terms and conditions of share-based payment arrangement [line items]
Dividend yield (%)
Contractual term of up to (years) | yr	6.5	6.5	6.5	6.5	6.5	6.5
Exercise multiple | $	$ 2		$ 2		$ 2
Weighted average share prices (NIS)				₪ 15.17		₪ 17.17
Bottom of range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility of the share prices (%)	37.00%	37.00%	32.00%	32.00%	42.00%	42.00%
Risk-free interest rate (%)	0.10%	0.10%	0.13%	0.13%	0.07%	0.07%
Weighted average share prices (NIS)		₪ 16.05
Expected average forfeiture rate (%)	1.00%	1.00%	0.00%	0.00%	0.00%	0.00%
Top of range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility of the share prices (%)	45.00%	45.00%	51.00%	51.00%	64.00%	64.00%
Risk-free interest rate (%)	1.83%	1.83%	1.83%	1.83%	2.04%	2.04%
Weighted average share prices (NIS)		₪ 16.44
Expected average forfeiture rate (%)	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%

TAXES ON INCOME (Narrative) (De

TAXES ON INCOME (Narrative) (Details) ₪ in Millions, $ in Millions	Jul. 10, 2016USD ($)	Jul. 10, 2016ILS (₪)	Dec. 31, 2016	Dec. 31, 2017USD ($)	Dec. 31, 2016	Dec. 31, 2015
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Useful life of intangible assets				five years
Reduced corporate tax				In 2017 from 25% to 24%, and in 2018 from 25% to 23%	26.5% to 25%
Agreement settlement amount	$ 1.3
Carry forward losses				$ 90.1
NIS [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Agreement settlement amount | ₪		₪ 5
Law for the Encouragement of Industry (Taxes), 1969 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Percentage of income that is generated from industrial enterprise				90.00%
Period of right to deduct expenses related to public offerings				Three years
Law for the Encouragement of Industry (Taxes), 1969 [Member] | patents, know-how and certain other intangible [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Useful life of intangible assets				Eight years
Law for the Encouragement of Capital Investments, 1959 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Reduced corporate tax				10% to 25% during the remaining five to eight years
Tax benefit description				The benefits period is limited to 12 years from completion of the investment or commencement of production ("Year of Operation"), or 14 years from the year in which the certificate of approval was obtained, whichever is earlier.
Law for the Encouragement of Capital Investments, 1959 [Member] | Development Zone A [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate				24.00%
Law for the Encouragement of Capital Investments, 1959 [Member] | Development Zone B [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate				10.00%
Law for the Encouragement of Capital Investments, 1959 [Member] | Alternative Track [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Reduced corporate tax				10% to 25% for the following five to eight years
Tax benefit description				The benefits period is limited to 12 years from the Year of Operation, or 14 years from the year in which the certificate of approval was obtained, whichever is earlier.
Tax benefits under Amendment 60 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate				15.00%
Tax benefit description				The duration of tax benefits is subject to a limitation of the earlier of 7 to 10 years (depending on the extent of foreign investment in the company) from the first year in which the company generated taxable income (at, or after, the Year of Election) , or 12 years from the first day of the Year of Election.
Dividend distributed during benefits period				Dividend is distributed during the benefits period or within the following 12 years (the limitation does not apply to a Foreign Investors Company, which is a company that more than 25% of its shares owned by non-Israeli residents).
Preferred Enterprise [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate			16.00%			16.00%
Percentage of minimum threshold export				25.00%
Preferred Enterprise [Member] | Development Zone A [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate						9.00%
Preferred Enterprise [Member] | Development Zone A [Member] | Bottom of range [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate			7.50%
Preferred Enterprise [Member] | Development Zone A [Member] | Top of range [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate			9.00%
2011 Amendment [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate				12.50%		20.00%
2011 Amendment [Member] | Development Zone A [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate				7.00%
Preferred technology enterprise [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate			12.00%
Preferred technology enterprise [Member] | Development Zone A [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate			7.50%
Special preferred technology enterprise [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate			6.00%
Dividends distributed from technology enterprise earnings [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax rate			4.00%

TAXES ON INCOME (Schedule of We

TAXES ON INCOME (Schedule of Weighted Combination of Applicable Rates) (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Rate of Reduced Tax	In 2017 from 25% to 24%, and in 2018 from 25% to 23%	26.5% to 25%
Percent of Foreign Ownership One [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Percent of Foreign Ownership	0-25%
Rate of Reduced Tax	25%
Reduced Tax Period	5 years
Tax Exemption Period	2 years
Percent of Foreign Ownership Two [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Percent of Foreign Ownership	25-49%
Rate of Reduced Tax	25%
Reduced Tax Period	8 years
Tax Exemption Period	2 years
Percent of Foreign Ownership Three [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Percent of Foreign Ownership	49-74%
Rate of Reduced Tax	20%
Reduced Tax Period	8 years
Tax Exemption Period	2 years
Percent of Foreign Ownership Four [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Percent of Foreign Ownership	74-90%
Rate of Reduced Tax	15%
Reduced Tax Period	8 years
Tax Exemption Period	2 years
Percent of Foreign Ownership Five [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Percent of Foreign Ownership	90-100%
Rate of Reduced Tax	10%
Reduced Tax Period	8 years
Tax Exemption Period	2 years

TAXES ON INCOME (Schedule of Cu

TAXES ON INCOME (Schedule of Current Taxes on Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of taxes on income [Abstract]
Current taxes	$ 129	$ 362
Taxes in respect of prior years	140	1,360
Taxes on income	$ 269	$ 1,722

SUPPLEMENTARY INFORMATION TO103

SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF PROFIT AND LOSS (Schedule of Additional Information about Revenues) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of major customers [line items]
Additional information about revenues	$ 102,825	$ 77,494	$ 69,906
Revenues from major customers each of whom amount to 10% or more, of total revenues [Member]
Disclosure of major customers [line items]
Additional information about revenues	60,383	50,676	36,338
Customer A - Proprietary products Segment [Member]
Disclosure of major customers [line items]
Additional information about revenues	60,383	40,451	26,032
Customer B - Proprietary products Segment and Distribution Segment [Member]
Disclosure of major customers [line items]
Additional information about revenues		$ 10,225	$ 10,306

SUPPLEMENTARY INFORMATION TO104

SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF PROFIT AND LOSS (Schedule of Revenues Based of Customers) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of geographical areas [line items]
Revenue	$ 102,825	$ 77,494	$ 69,906
U.S.A. [Member]
Disclosure of geographical areas [line items]
Revenue	60,405	40,585	26,559
Israel [Member]
Disclosure of geographical areas [line items]
Revenue	26,355	25,340	30,624
Europe [Member]
Disclosure of geographical areas [line items]
Revenue	5,348	3,825	3,223
Latin America [Member]
Disclosure of geographical areas [line items]
Revenue	5,248	4,221	6,036
Asia [Member]
Disclosure of geographical areas [line items]
Revenue	4,979	3,028	2,900
Others [Member]
Disclosure of geographical areas [line items]
Revenue	$ 490	$ 495	$ 564

SUPPLEMENTARY INFORMATION TO105

SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF PROFIT AND LOSS (Schedule of Income and Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cost of goods sold
Cost of materials	$ 41,179	$ 36,154	$ 38,848
Salary and related expenses	13,137	10,596	9,991
Depreciation and amortization	2,504	2,443	2,383
Energy	1,202	959	922
Subcontractors	3,995	2,833	2,112
Other manufacturing expenses	1,572	1,057	1,220
Total expenses	63,589	54,042	55,476
Decrease (increase) in inventories	7,148	2,092	(935)
Total cost of revenues	70,737	56,134	54,541
Research and development
Salary and related expenses	6,413	5,237	4,566
Subcontractors	3,392	8,318	8,002
Materials and allocation of facility costs	1,101	1,907	3,386
Others	1,067	783	576
Research and development expenses	11,973	16,245	16,530
Selling and marketing
Salary and related expenses	1,470	1,272	1,227
Marketing support	95	79	368
Packing, shipping and delivery	607	494	454
Marketing and advertising	627	337	560
Registration and marketing fees	1,162	796	794
Others	437	265	249
Selling and marketing expenses	4,398	3,243	3,652
General and administrative
Salary and related expenses	3,138	3,029	2,604
Employees welfare	2,182	1,465	1,391
Professional fees	1,497	1,378	1,482
Depreciation, amortization and impairment	649	712	524
Others	807	769	606
General and administrative expenses	8,273	7,353	6,607
Financial incomes
Interest income and gains from marketable securities	500	469	463
Financial expenses
Interest and amortization from debentures			731
Fees and interest paid to financial institutions	162	126	111
Others			92
Financial expense	$ 162	$ 126	$ 934

INCOME (LOSS) PER SHARE (Schedu

INCOME (LOSS) PER SHARE (Schedule of Details of Number of Shares and Income (Loss)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income (loss) per share attributable to equity holders of the Company:
Weighted Number of Shares For the computation of basic income (loss)	37,970,697	36,418,833	36,245,813
Weighted Number of Shares Effect of potential dilutive ordinary shares	74,400
Weighted Number of Shares For the computation of diluted income (loss)	38,045,097	36,418,833	36,245,813
Loss Attributed to equity holders of the Company For the computation of basic income (loss)	$ 6,901	$ (6,733)	$ (11,270)
Loss Attributed to equity holders of the Company Effect of potential dilutive ordinary shares
Loss Attributed to equity holders of the Company For the computation of diluted income (loss)	$ 6,901	$ (6,733)	$ (11,270)

OPERATING SEGMENTS (Schedule of

OPERATING SEGMENTS (Schedule of Reporting on Operating Segments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of operating segments [line items]
Revenues	$ 102,825	$ 77,494	$ 69,906
Gross profit	32,088	21,360	15,365
Unallocated corporate expenses	(24,644)	(26,841)	(26,789)
Finance income, net	(274)	470	154
Income before taxes on income	7,170	(5,011)	(11,270)
Proprietary Products [Member]
Disclosure of operating segments [line items]
Revenues	79,559	55,958	42,952
Gross profit	28,224	18,235	12,051
Distribution [Member]
Disclosure of operating segments [line items]
Revenues	23,266	21,536	26,954
Gross profit	$ 3,864	$ 3,125	$ 3,314

BALANCES AND TRANSACTIONS WI108

BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Narrative) (Details)	1 Months Ended				12 Months Ended
	Aug. 30, 2016USD ($)	Aug. 30, 2016ILS (₪)	Jun. 30, 2015USD ($)	Jun. 30, 2015ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Disclosure of transactions between related parties [line items]
Allowance for doubtful accounts for sums receivable from related parties
Chief Executive Officer [Member]
Disclosure of transactions between related parties [line items]
Monthly gross salary	$ 18,430
Chief Executive Officer [Member]
Disclosure of transactions between related parties [line items]
Monthly gross salary			$ 16,658
Annual bonus					$ 127,000
Chief Executive Officer [Member] | NIS [Member]
Disclosure of transactions between related parties [line items]
Monthly gross salary | ₪		₪ 71,500		₪ 65,000

BALANCES AND TRANSACTIONS WI109

BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Schedule of Balances with Related Parties) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of transactions between related parties [abstract]
Other accounts payables	$ 292	$ 230
Employee benefit liabilities, net	92	170
Trade receivable	$ 2,382	$ 675

BALANCES AND TRANSACTIONS WI110

BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Schedule of Benefits to Related Parties) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Disclosure of transactions between related parties [abstract]
Salary and related expenses to those employed by the Company or on its behalf	$ 460	$ 473
Salary of directors not employed by the Company or on its behalf	$ 107	$ 122
Related and related parties employed by the Company or on its behalf	2	2
Directors not employed by the Company	2	3
Number of People to whom the Salary and Benefits Refer	4	5

BALANCES AND TRANSACTIONS WI111

BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Schedule of Benefits to Key Executive Personnel) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of transactions between related parties [abstract]
Short-term benefits	$ 2,719	$ 2,453	$ 2,144
Share-based payment	310	460	650
Other long-term benefits	6	28	61
Benefits to key executive personnel	$ 3,035	$ 2,941	$ 2,855

BALANCES AND TRANSACTIONS WI112

BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Schedule of Transactions with Related Parties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of transactions between related parties [abstract]
Sales	$ 3,455	$ 2,230	$ 2,795
Selling and marketing expenses	121	101	114
General and administrative expenses	$ 446	$ 503	$ 526